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I. INTRODUCTION 
The main theme of this thesis is understanding mitochondrial 
permeability transition and mitochondrial glutathione status in 
relationship to mitochondrial energy status. 
Mitochondria contain a pool of glutathione which is discrete from 
the cytosolic compartment. Although little is understood about its 
regulation, changes in mitochondrial glutathione in-vitro have been 
linked with a disruption in intracellular Ca2+ homeostasis. Under these 
conditions, loss of mitochondrial glutathione occurs by an unidentified 
mechanism, which correlates with loss of cell viability. 
This thesis explores one possibility by which mitochondrial Ca2+ 
homeostasis may alter mitochondrial glutathione and energy status. The 
mechanism of such an alteration involves activation of a putative Ca2+­
dependent, cyclosporin A-sensitive mitochondrial inner membrane pore. 
Activation or opening of a putative pore is referred to as permeability 
transition. Many different agents, in the presence of Ca2+, can "induce" 
permeability transition. Examples include inorganic phosphate, t-butyl 
hydroperoxide, and some heavy metals. 
Chapter II provides background perspectives and current literature 
pertinent to the research presented in the following chapters. The chapter 2 
begins with a discussion of mitochondrial function in aerobic metabolism 
and Ca2+ transport. The second part of the chapter introduces the 
concept of mitochondrial permeability transition, and ties that concept to 
the role of disrupted Ca2+ homeostasis and mitochondrial glutathione 
status in irreversible cell injury. Next is a discussion of the relationship 
of mitochondrial glutathione and endogenous oxidative stress. At the 
end is a brief section describing the purpose of this research. The main 
section of this chapter is a contribution to a book entitled "Proceedings of 
the Paul Hochstein Festschrift Conference" which is to be published 
shortly. The title of the manuscript submitted is "Oxidative Stress and 
Mitochondrial Permeability Transition". 
A presentation of the research findings begin in Chapter III, which 
describes the rapid and nearly complete release of mitochondrial 
glutathione during Ca2+- and inorganic phosphate-induced permeability 
transition. Also explored in Chapter III is the ability to load isolated 
mitochondria with exogenous glutathione by the controlled opening and 
closing of this putative Ca2+-dependent pore. This chapter has been 
published (Arch. Biochem. Biophys. 290: 51-56, 1991.) 
Chapter IV demonstrates that permeability transition can occur 
without large amplitude swelling. Large amplitude swelling has been a 
generally accepted characteristic of permeability transition.  Following the 
addition of metabolic inhibitors, large amplitude swelling is alleviated in 
permeability transition induced mitochondria; however, mitochondrial 
glutathione is released to varying degrees, suggesting that mitochondrial 
glutathione release may be a sensitive indicator of permeability 3 
transition. This chapter will be submitted to Archives of Biochemistry 
and Biophysics. 
Chapter V describes a novel finding involving the effect of 
inorganic phosphate induced permeability transition on pyridine and 
adenine nucleotides. Pyridine nucleotide redox status was previously 
thought to be unaffected by inorganic phosphate during permeability 
transition, and is often used in comparison to agents, such as t­
butylhydroperoxide, that alters this redox ratio; however, the findings 
presented in this chapter demonstrate that pyridine nucleotides undergo 
extensive oxidation in the presence of inorganic phosphate. Also 
demonstrated is the rapid depletion of ATP and ADP, with concomitant 
formation of AMP. This chapter will be submitted to Biochemical and 
Biophysical Research Communications. 
Chapter VI explores whether pyridine nucleotides, which are 
normally impermeable to the inner mitochondrial membrane, efflux 
during permeability transition. Also examined in this chapter is the effect 
of metabolic inhibitors on pyridine and adenine nucleotide status during 
Ca2+ and Pi-induced permeability transition.  This chapter will be 
submitted to Biochemistry Journal. 4 
II. BACKGROUND PERSPECTIVES 
Mitochondria 
Background Information 
The primary function of mitochondria is aerobic respiration and 
energy metabolism. Mitochondria are cytosolic organelles present in 
nearly all eukaryotic cells of higher animals and plants, and certain 
microorganisms including algae, protozoa, and fungi. An accepted theory 
on the evolutionary origin of mitochondria is the endosymbiotic theory 
which hypothesizes that invasion of bacteria into ancestral prokaryotic 
cells resulted in present day aerobic respiration (1). [A common 
misconception is that mitochondria are present in all eukaryotic cells. 
More than a thousand species of protozoa and a few fungi have no 
mitochondria (2). Red blood cells of mammals also lack mitochondria.] 
The tissue most frequently used as a laboratory source of freshly 
isolated mitochondria is the rat liver; each parenchymal cell contains an 
average of 1300 mitochondria comprising 17% of the total cellular 
volume (3). As a tribute to their small size (approximately 4.4 p.m X 0.45 
jam), 7.2 X 109 mitochondria per milligram of protein are present in a 
typical suspension of isolated mitochondria (4). 
Mitochondrial Structure 
Mitochondria are highly compartmentalized organelles with two 
membranes (Figure II. 1). The outer membrane contains pores that allow 
equilibration of the inner membrane space with the 5 
extramitochondrial environment, whereas the inner membrane is 
impermeable to most substances. Transport of most substances into and 
out of the matrix is mediated by numerous specific intermembrane 
protein carriers (Figure II. 2). Approximately 70% of the inner membrane 
is composed of proteins that are mainly transmembrane carriers or part of 
the respiratory chain (Figure II. 2, 3). The remaining 30% are 
phospholipids, primarily phosphatidylcholine and 
phosphatidylethanolamine, with a small proportion as cardiolipin (5). 
Mitochondrial Calcium Transport 
Mitochondria play an important role in the regulation of several 
ions, primarily H+, Ca2+, but also Na+, K+, Cl', and Mg2+. The central 
role of mitochondria in regulating intracellular Ca2+ is interesting, since 
mitochondria have a high capacity to take up Ca2+, as well as release Ca2+ 
(6-8). The finding that the endoplasmic reticulum has a higher affinity for 
Ca2+ (although lower capacity) has led some to propose that the 
endoplasmic reticulum is a more important participant in the dynamic 
regulation of intracellular Ca2+ (9). Proteins, such as calmodulin, are also 
capable of responding to changing Ca2+ levels and, therefore, may also 
contribute to the regulation of this ion. 
Mitochondrial Ca2+ uptake and release occur by separate 
mechanisms (Figure II. 4) (10). Uptake is mediated by the electrophoretic 
uniporter, located on the inner membrane of mitochondria (11-12).  It is 
driven by the membrane potential (-180 mV, negative inside) that is set 
up through the extrusion of H+ from the matrix to the inner membrane 
space. The uptake of Ca2+ via the uniporter is noncompetitively 6 
inhibited by the glycoprotein stain, ruthenium red (14). In addition, 
lanthanide ions are also inhibitors of the Ca2+ uniporter (15). 
The Ca2+ efflux pathway primarily involves the Na+-Ca2+ 
antiporter, which is driven by the exchange of Na+ for H+ (Figure II. 4) 
(10, 16). Functioning of this pathway depends upon the pH component of 
the proton motive force, and also appears to be regulated by the redox 
state of pyridine nucleotides, with oxidation favoring Ca2+ release (10, 17). 
A second Ca2+ efflux mechanism may also exist, involving direct Ca2+­
2H+ exchange; but it is poorly understood at this time (Figure II. 4) (10, 
13). 
Due to separate processes of uptake and release of Ca2+, 
mitochondria can presumably cycle Ca2+ by uptake, release and 
subsequent reuptake (10, 18). This process probably does not occur to any 
significant extent in normal mitochondria, as cycling of Ca2+ is an energy 
dissipating process that may cause a collapse of the membrane potential. 
However, under pathological conditions where intracellular Ca2+ 
homeostasis is disrupted, it is hypothesized that the mitochondria do 
cycle Ca2+, thereby promoting irreversible cell injury (18-19). 
A role for disrupted Ca2+ homeostasis in irreversible cell injury 
has been clearly shown under a variety of experimental conditions, 
ranging from chemically induced cytotoxicity to ischemia and 
reperfusion injury (20-25). The degree to which mitochondria and their 
ability to sequester Ca2+ contribute to cellular injury, especially in  vivo, is 
less clear. 
However, the ability of mitochondria to accumulate Ca2+ in vitro 
can result in pathological consequences to mitochondria under certain 7 
experimental conditions. This is the major thrust of this thesis. One 
pathway appears to be the activation of a Ca2±-dependent pore in the 
inner membrane of mitochondria. The opening of this pore results in 
disruption of the inner membrane permeability barrier required for 
normal functioning. Among other things, opening or activation of this 
pore allows the release of mitochondrial Ca2+, as well as other matrix 
solutes. Although the physiological functions of this pore remains 
obscure, its pathological relevance, as discussed below, may be important. 8 
Mitochondrial Permeability Transition 
Background Information 
Ca2+ damage to mitochondria was recognized shortly after work 
with isolated mitochondria began in the 1950's (26). Hunter and Haworth 
proposed that loading of Ca2+ into the mitochondria caused the opening 
of a hydrophilic channel in the inner membrane, allowing the passage of 
small molecules less than 1200 Da (27-29). It is now well accepted that 
mitochondria from a variety of tissues contain a Ca2 + - dependent inner 
membrane pore. The Ca2+-dependent pore is approximately 20 A in 
diameter when opened, resulting in the permeability of the inner 
membrane barrier (10, 30-33). This process is referred to as mitochondrial 
permeability transition. 
Characteristics of Permeability Transition 
Some of the well known biochemical characteristics of the Ca2+­
dependent permeability transition include: nonspecific inner membrane 
permeability to small solutes with molecular weight less than 1200 Da; 
large amplitude swelling; and the uncoupling of oxidative 
phosphorylation (10, 33). More recently, it has become apparent that 
proteins appear to traverse the inner membrane pore, although at a much 
slower rate than small matrix solutes (34). 
In vitro activation or regulation of the pore occurs in the presence 
of Ca2+ and a second agent, termed an "inducing agent". Many inducing 
agents have been identified, and vary greatly in both structure and 
function (10, 35-37). Examples of inducing agents include near 9 
physiological levels of inorganic phosphate, fatty acids, some heavy 
metals, organic sulfhydryl reagents, and oxidants, such as t-butyl 
hydroperoxide and hydrogen peroxide (10). The pore is thought to be 
activated under several different conditions involving (1) oxidative stress 
due to the oxidation of pyridine nucleotides by agents such as t-butyl 
hydroperoxide (38-41); (2) depletion of adenine nucleotides by 
pyrophosphate and phosphoenolpyruvate (42-44); (3) and by agents such 
as inorganic phosphate which are thought to have an intramitochondrial 
site of action (45-49). These different inducing agents, in the presence of 
Ca2+, may act however through a common mechanism to induce inner 
membrane permeability by altering the conformation of the putative pore 
structure, as discussed below. 
During permeability transition, Ca2+ as well as other solutes are 
rapidly released from the mitochondrial matrix, presumably via diffusion 
through pore opening (28-33). Following the release of matrix solutes, a 
colloidal osmotic pressure arises in the mitochondrial matrix, due to the 
high concentration of proteins that are slow to equilibrate (10, 34)). In 
order to correct the osmotic imbalance, entrance of H2O results in 
massive swelling of the mitochondria (10). 
Mitochondrial swelling under these conditions is termed large 
amplitude swelling. Although large amplitude swelling is a secondary 
event, it occurs within a short time (3-10 min) and is easily detected by 
monitoring the loss in absorbance of mitochondrial suspensions (50). 
Monitoring of mitochondrial swelling at 540 nm is a convenient assay, 
and it is often utilized as an indicator of permeability transition (51-52). 10 
Inhibition of Permeability Transition by Cyclosporin A 
A recent significant finding is that the immunosuppressive drug, 
cyclosporin A (CsA), is a potent inhibitor of the Ca2+-induced 
permeability transition (53-56). CsA, a cyclic peptide, is a fungal 
metabolite which suppresses T-cell lymphocyte function by binding to the 
cellular receptor, cyclophilin or peptidyl-prolyl-cis-trans-isomerase (PPI) 
(57-58). CsA is currently in use as a potent clinical agent for preventing 
rejection of transplanted organs (59). 
Studies by Fournier et al. (60) showed that CsA treatment promotes 
retention of accumulated Ca2+ within isolated rat liver mitochondria. 
Work by Crompton and coworkers (53) revealed that CsA is a potent 
inhibitor of the permeability transition induced by either inorganic 
phosphate or t-butyl hydroperoxide in the presence of Ca2+. Broekemeier 
et al. (54) tested CsA as an inhibitor of the inner membrane pore in the 
presence of many different inducing agents and found that very low 
concentrations of CsA acted to protect against permeability transition. 
These studies all demonstrate the potency of CsA in preventing the 
permeability transition with concentrations as low as 100 pmoles CsA/mg 
mitochondrial protein. 
Possible Mechanism of CsA Inhibition of Permeability Transition 
The inhibition of pore opening is linear to the concentration of 
CsA, suggesting a 1:1 stoichiometry to some component of the pore which 
is present at approximately 100 pmoles/mg protein (61-63). A likely 
mitochondrial target for CsA is the matrix protein PPI, or cyclophilin. PPI 
has been identified in the mitochondrial matrix in concentrations of 100 11 
pmoles/mg protein (61,63-64). As a peptide bond isomerase, PPI inverts 
the cis-trans configuration at proline residues and therefore is  thought to 
play a role in protein folding (65-66). 
The role of PPI in permeability transition is thought to involve the 
binding of PPI to the putative pore structure or a related component, 
thereby stimulating or catalyzing pore formation (61, 63). Halestrap et al. 
propose that PPI binds to a proline residue on the adenine nucleotide 
translocase dimer in the presence of Ca2+ and an inducing agent. This is 
thought to result in a conformational change of the carrier that promotes 
pore activity (61, 63). 
Proposed Mechanisms of Inner Membrane Permeability 
Several mechanisms for the inner membrane permeability defect 
have been proposed. Perhaps the most widely accepted view is that the 
inner membrane permeability is nonspecific in nature. Studies by 
Halestrap and co-workers (33, 61, 63-64) have focused on the connection 
between the adenine nucleotide translocase and pore formation. They 
have proposed the adenine nucleotide translocase dimer  as the putative 
pore structure (61). They suggest that the binding of negative effectors 
such as Ca2+, PPI, and inducing agents results in a conformational change 
of the adenine nucleotide translocase dimer from the  "m" conformation 
(nonpermeable state) to the "c" conformation. It is proposed that the "c" 
conformation favors pore formation and agents, such as atractyloside, 
which are known to induce the "c" conformation of the adenine 
nucleotide translocase, promote inner membrane permeability (33, 61). 
This results in a conformational change of the adenine nucleotide 12 
translocase which enables functioning as a nonspecific pore. Conversely, 
compounds which stabilize the "m" conformation, such as bongkrekic 
acid and ADP, prevent inner membrane permeability (33, 61). 
Collapse of the membrane potential is a second mechanism 
thought to mediate the nonspecific permeability transition. Bernardi and 
colleagues (67-69) report that permeability transition can be controlled by 
collapse of the membrane potential. They suggest that collapse of the 
membrane potential is a cause, rather than a consequence of the 
permeability transition. 
As the third possible mechanism, Richter et al. (70-73) have 
proposed that pore formation is not required for the inner membrane 
permeability. Their findings suggest two things; 1) that an inner 
membrane defect provides for a specific Ca2+ release pathway and 2) that 
mono ADP-ribosylation of critical inner membrane proteins is the 
responsible mechanism of permeability transition. They hypothesize that 
Ca2+ cycling, in the presence of oxidants such as t-butyl hydroperoxide, 
results in NAD(P)H oxidation followed by the hydrolysis of NAD+ to 
nicotinamide and ADP-ribose. Subsequent ADP-ribosylation of one or 
more critical proteins results in the specific release of Ca2+. This work is 
also supported by Weis et al. who report that n-acetyl-p-benzoquinone 
imine induces mitochondrial Ca2+ release by the hydrolysis of oxidized 
pyridine nucleotides. (74) 
Of all three mechanisms discussed, it appears that the current, and 
probably most accepted, understanding of permeability transition is that 
the pore structure is an allosteric inner membrane protein, perhaps the 
adenine nucleotide translocase dimer or some related component. In this 13 
view, the putative pore structure has several different regulatory sites; 
this possibly explains why many different compounds, including Ca2+, 
inorganic phosphate, oxidants, sulfhydryl reagents, heavy metals, ADP, 
ATP, atractyloside, and bongkrekic acid, either inhibit or promote the 
permeable state. Whether permeability transition occurs may depend 
upon which sites are modified. 
Physiological Relevance of a CaLt-Dependent Pore 
Whether the process of pore formation has a physiological function 
remains an unanswered and intriguing question. It is proposed that 
regulated opening and closing of an inner membrane pore could provide 
a way to load or release mitochondrial metabolites for which no other 
transport means is available (61, 63). Pathological functions of such a pore 
may also play a role in mitochondrial self-destruction during oxidative 
stress or Ca2+ overload to assure destruction of damaged tissue and may 
therefore be a component of programmed cell death or apoptosis (33). If 
the pore has a physiological function, it is likely that permeability 
transition, as observed experimentally, represents pathological 
consequences, perhaps associated with disrupted Ca2+ homeostasis. At 
this time, however, no evidence exist for the reversibility of permeability 
transition. 14 
Cellular Injury, Calcium Homeostasis, 
and Mitochondrial Glutathione 
Cellular Studies of Permeability Transition 
Several studies have explored whether permeability transition 
occurs during irreversible cell injury caused by chemically induced 
cytotoxicity as well as ischemia and reperfusion injury. In these studies, 
the prevention of cell injury by CsA is causally linked to permeability 
transition occurring at the cellular level. Imberti et al. (76) reported that 
oxidant-induced hepatocyte injury is prevented by the combined actions 
of CsA and a phospholipase inhibitor (either trifluoperazine, mepacrine, 
or dibucaine), both known inhibitors of oxidant induced mitochondrial 
permeability transition (76). In another recent report by Kass and co­
workers (19), CsA protected hepatocytes from pro-oxidant injury, possibly 
by preventing Ca2+ cycling and subsequent mitochondrial dysfunction. 
Pretreatment of hepatocytes with CsA followed by exposure to either t­
butylhydroperoxide, cumene hydroperoxide, or 3,5-dimethyl-N-acetyl-p­
benzoquinone imine prevented the loss of cell viability. Determination 
of intracellular Ca2+ pools suggested that mitochondrial Ca2+ depletion 
was an early event which was prevented by CsA (19). 
Broekemeier et al. (78) demonstrated that CsA prevented 
hepatotoxicity of t-butyl hydroperoxide in the presence of high 
extracellular Ca2+ (10 mM Ca2±) but not at physiological Ca2+ 
concentrations (2.5 mM). Recent studies by Snyder et al. (79) 
demonstrated with cultured hepatocytes that CsA protected against the 
toxic consequences of the mitochondrial poison, 1-methy1-4­
phenylpyridinium. Their findings showed that atractyloside, in the 15 
presence of CsA, eliminated the observed protective effects of CsA, 
leading to their conclusion that permeability transition is linked to the 
loss of cell viability in this model (79). It was also shown recently that low 
concentrations of CsA prevented irreversible damage to isolated myocytes 
induced by prolonged hypoxia and subsequent reoxygenation (80). 
Disrupted Ca2± Homeostasis and Mitochondrial Glutathione 
Mechanisms of acute irreversible cell injury and death have long 
been a subject of interest. Pathologists have recognized for many years 
that cells of necrotic tissue accumulate Ca2+ (81). It was later proposed 
that a wide variety of toxic agents ultimately act by a final common 
pathway, characterized by an increased influx of Ca2+ across the plasma 
membrane, resulting in cellular pathogenesis and death (82-83). 
As the role of Ca2+ in mediating cellular death was further 
investigated, studies suggested that the disruption of intracellular Ca2+ 
homeostasis, rather than the influx of Ca2+, was directly linked to the 
expression of toxicity (84-85). Pro-oxidant compounds such as menadione, 
t-butyl hydroperoxide, and acetaminophen were shown to directly affect 
intracellular Ca2+ homeostasis by inhibiting the Ca2+-ATPase of either 
the plasma membrane (menadione and acetaminophen)  or the 
endoplasmic reticulum (t-butyl hydroperoxide) (84-85). Whether 
oxidative stress results in the loss of Ca2+ homeostasis  or whether 
disrupted Ca2+ homeostasis causes oxidative stress, remains to be fully 
understood. However, the two processes appear linked in some way. 
Several studies have suggested that mitochondrial glutathione 
plays a critical role in cell viability during conditions involving disrupted 16 
Ca2+ homeostasis (86-87, 92-95). Meredith and Reed first proposed a role 
for mitochondrial glutathione in cytotoxicity after observing that 
depletion of cytosolic glutathione did not affect cell viability; whereas, 
depletion of mitochondrial and cytosolic glutathione correlated with the 
onset of cell injury (86). Leakage of the cytosolic enzyme lactate 
dehydrogenase, a marker of irreversible cell injury, increased markedly 
when mitochondrial glutathione was depleted to less than 10% of the 
initial value (87). Other reports have shown that cytotoxicity, as 
measured by lipid peroxidation, liver necrosis, and loss of cellular 
enzymes in vivo and in vitro occurred only if the cellular glutathione 
levels fell below 10-15% of the initial value (88-91). This value 
corresponds to the percentage of total glutathione associated with the 
mitochondria. 
Studies have shown that isolated hepatocytes incubated in the 
absence of extracellular Ca2+, under an atmosphere of 
95% 02/5% Cot, undergo an acute oxidative stress (92-95). This was 
indicated by an increase in lipid peroxidation, a decrease in both cytosolic 
and mitochondrial glutathione, and a loss of vitamin E as well as an 
increase in both K+ and lactate dehydrogenase leakage. Cells were 
protected from injury when incubated in the presence of chelators of 
either Ca2+ or Fe3+, antioxidants, ruthenium red, and lanthanides (92­
95). The effect of the latter two compounds implies that the electrogenic 
influx of Ca2+ into the mitochondria is involved. Thus the absence of 
extracellular Ca2+ induces a potent and acute oxidative stress, possibly by 
the disruption of mitochondrial Ca2+ handling. 17 
The results from these studies (92-95) suggest that mitochondria are 
target organelles for the expressed toxicity as suggested by the near 
complete loss of mitochondrial glutathione by an unknown mechanism, 
which correlated with the onset of irreversible cell injury. A second 
indication that mitochondria are likely targets for the injury associated 
with the Ca2+ omission model of oxidative stress was the loss of the 
mitochondrial membrane potential (95). Most of the agents that 
prevented loss of mitochondrial glutathione and irreversible cell injury 
also prevented the collapse of the membrane potential, suggesting a role 
for mitochondrial Ca2+ homeostasis. 18 
Glutathione
 
Discovery and Functions 
Glutathione was discovered a little more than a century ago.  In 
1888, deRey-Pailhade (96-97) reported that yeast cells contain a substance 
responsible for the reduction of sulfur to hydrogen sulfide. He named 
this substance "philothion" from the Greek words  for "love" and 
"sulfur." He suggested this substance must have an important biological 
role due to its ubiquity in the diverse biological samples he examined. 
It was soon proposed by Heffter (98) and Arnold (99) that the 
compound responsible for the reducing properties of the yeast cell was 
cysteine. Further work revealed that the substance was water soluble and 
possibly a dipeptide containing glutamate and cysteine. Hopkins renamed 
this compound glutathione and later found that glycine was also present 
(100-101). The structure of glutathione (Figure II. 5) was deduced from 
chemical studies and confirmed by synthesis (102-103). Reference to 
glutathione or GSH indicates the reduced form of glutathione throughout 
this manuscript. 
Today, we know that glutathione, a nonprotein thiol,  is present in 
millimolar concentration within cells of animals, plants, and 
microorganisms. Glutathione often functions as a first line of cellular 
defense against reactive oxygen species, radiation- induced free radicals, 
and reactive xenobiotic metabolites (104-105). Although glutathione is 
most often considered in light of cellular protection and detoxification, it 
participates in the formation of toxic cellular metabolites, particularly 
with several halogenated compounds (106-107). The focus of this 19 
remaining discussion will be regarding biosynthesis of glutathione, 
cellular protection of glutathione against reactive oxygen species, and its 
particular role in mitochondria. 
Biosynthesis of Glutathione 
Enzymatic biosynthesis of glutathione is energy dependent and 
occurs from its constitutive amino acids in the cytosolic compartment of 
perhaps all mammalian tissues (111).  It is thought that glutathione 
synthesis in the liver is limited by the availability of cysteine (0.2-0.5 mM) 
(108). 7-Glutamyl-cysteine synthetase, in the presence of ATP, catalyzes 
the rate-limiting step in which glutamic acid and cysteine are covalently 
linked through the atypical 7-carboxyl-derived peptide bond (109) 
(Equation II. 1A). This unusual linkage makes glutathione resistant to 
hydrolytic cleavage of proteases and aminopeptidases and protects the 
thiol on cysteine from rapid oxidation. 
The glycine residue, thought to protect glutathione from the 
actions of y-glutamyl-cyclotransferase, is added enzymatically, forming the 
tripeptide, in the presence of glutathione synthetase and ATP (109) 
(Equation II. 1B).  Breakdown of glutathione occurs extracellularly by the 
enzymatic action of y- glutamyl transpeptidase and dipeptidases that occur 
mainly at the luminal surface of the brush border membrane in the 
kidney (109). 20 
y-glutamylcysteine synthetase 
A. L-glutamate + L-cysteine + ATP > L-y-glutamyl-L-cysteine + ADP + Pi 
glutathione synthetase 
B. L-y-glutamyl-L-cysteine + glycine + ATP > glutathione + ADP + Pi 
Equation II. 1. Biosynthesis of Glutathione 
Glutathione Compartmentation and Function  in Mitochondria 
In hepatocytes, glutathione is found in the cytosol and 
mitochondria as separate, nonequilibrated pools (86, 104), whereas nuclear 
glutathione is in equilibrium with the cytosol (110). Glutathione is 
present in millimolar concentrations as reduced glutathione (GSH) with 
minor fractions present as either glutathione disulfide (GSSG), mixed 
disulfides of glutathione and protein thiols, or thioethers (111). 
It is thought that glutathione synthesis takes place in the cytosol 
because activity of y-glutamylcysteine synthetase and glutathione 
synthetase have not been detected in mitochondrial  fractions.  It therefore 
appears that cytosolic glutathione is transported into the mitochondria. 
Studies of hepatic mitochondrial glutathione transport by Kurosawa et al. 
and Martensson and Meister have previously demonstrated that 
glutathione uptake is energy-dependent, requiring both the 
mitochondrial membrane potential and the presence of the pH gradient 
(112-113). Mitochondrial glutathione transport in extrahepatic tissues 21 
may be different, as suggested by McKernan et al. (114). They reported that 
uptake of glutathione by renal cortical mitochondria is electroneutral, 
involving counter ion transport with dicarboxylic acids and independent 
of the membrane potential (114). 
Several studies have shown that mitochondrial glutathione 
functions as a discrete pool from cytosolic glutathione as first suggested by 
Vignais and Vignais (115). A report by Jocelyn (116) demonstrated that 
mitochondrial glutathione is impermeable to the inner membrane 
following isolation of mitochondria, suggesting that mitochondrial 
glutathione status is highly regulated and possibly energy-dependent. 
Studies by Meredith and Reed (86) demonstrated different rates of hepatic 
glutathione turnover between the cytosol and mitochondria, supporting 
the earlier contention of separate intracellular glutathione pools. Their 
findings indicated that the half-life for mitochondrial glutathione is 30 
hours vs. 2 hours for cytosolic glutathione. Although mitochondria 
contain approximately 10-15% of the total cellular glutathione pool,  the 
concentration of mitochondrial glutathione (10 mM) is higher than  that 
observed in the cytosol (7 mM) (117). 
The observation that mitochondrial glutathione is more 
concentrated than cytosolic glutathione may suggest that its biological role 
in mitochondria is of significance to cellular homeostasis. Perhaps the 
most significant function of mitochondrial glutathione is the 
detoxification of endogenously formed hydrogen peroxide (118-120) to 
water via the glutathione redox cycle (Figure II. 6). Although catalase 
activity was recently demonstrated in heart mitochondria, (122), liver 
mitochondria do not contain catalase (121), and therefore we may assume 22 
that a primary function of mitochondrial glutathione is for the 
detoxification of endogenously produced H202 (discussed below). The 
glutathione redox cycle requires the enzymes GSH peroxidase (selenium 
containing) and GSSG reductase along with the cofactors GSH and 
NADPH (Figure II. 6) (123-124). 
Another important function of mitochondrial glutathione is 
maintenance of protein thiols (104, 111). Mitochondria contain about 100 
nmol of total thiol per mg of protein with nearly 95% being associated 
with protein and the remaining 5% as nonprotein thiol, mostly 
glutathione (125-126). Sulfhydryl groups are essential for the activity of 
nearly all metabolic carriers associated with the inner membrane of 
mitochondria. Oxidation of these essential sulfhydryls generally leads to 
inhibition of transporting capacity that can result in mitochondrial 
dysfunction (126). 
The ratio of GSH:GSSG in mitochondria is approximately  18:1 
under normal (untreated) conditions. Unlike cytosolic GSSG, 
mitochondrial GSSG is not effluxed from the matrix compartment (127). 
Olafsdottir and Reed (127) demonstrated that during oxidative stress 
induced with t-butyl hydroperoxide, GSSG is accumulated in the 
mitochondrial matrix and is eventually reduced back to GSH. However, 
as the redox state of the mitochondria increased, an increase in protein 
mixed disulfides was also observed. It was concluded that mitochondria 
are more sensitive to redox changes in GSH:GSSG than the cytosol and 
therefore mitochondria may be more susceptible to the damaging effects 
of oxidative stress. These findings lend credence to the suggestions that, 
under certain experimental conditions, irreversible cell injury due to 23 
oxidative challenge may result from irreversible mitochondrial 
dysfunction. 
Endogenous Oxidative Stress of Mitochondria 
Nearly 90% of the total 02 consumed by mammalian species is 
delivered to mitochondria where a 4-electron reduction to H2O by the 
electron transport chain is coupled to ATP synthesis (Figure II. 3) (118­
120). Nearly 4% of the mitochondrial 02 is incompletely reduced, due to 
the leakage of electrons along the respiratory chain.  Incomplete reduction 
forms toxic reactive oxygen species such as the superoxide radical (02-), 
hydrogen peroxide (H202), singlet oxygen (102), and hydroxyl radical 
(HO) (118-120). Without mitochondrial antioxidant defense systems such 
as the glutathione redox cycle (Figure II. 6), aerobic metabolism, an 
essential process for life in many species, would likely be impossible due 
to reactive oxygen species. 
The superoxide radical undergoes disproportionation to H202 and 
02 via the Mn-containing superoxide dismutase.  This reaction can also 
take place nonenzymatically, but at a rate approximately four orders of 
magnitude less at pH 7.4 (128).  Richter (129) calculated that during 
normal metabolism, one rat liver mitochondrion produces 3 X 107 
superoxide radicals per day. It is estimated that superoxide and hydrogen 
peroxide steady state concentrations  are in the picomolar and nanomolar 
range, respectively (130). Jones and co-workers (131) have estimated the 
hepatocyte steady state H202 concentration to be as high as 25 AM. If 
H202 is not detoxified to H2O, formation of HO- can occur by metal (iron) 
catalyzed Haber Weiss or Fenton type reactions (Equation II. 2) (132). The 24 
HO. species is one of the most reactive and short lived biological radicals 
and has the potential to initiate lipid peroxidation of biological 
membranes (132-133), although not as effectively as other radicals, e.g., the 
ROO radical (134). Unless termination reactions occur, the process of 
lipid peroxidation will propagate, resulting in potentially high levels of 
oxidative stress. Therefore, detoxification of endogenously produced 
H202 is critical for redox maintenance of mitochondrial as well as cellular 
homeostasis. 
A. Haber Weiss Reaction  02 + H202 + Fe3+ ---> 02 + OH- + HO. + Fe2+ 
B. Fenton Reaction  H202 + Fe2+ -- - -> HO. + Fe3+ 
Equation II. 2. 
Statement of Purpose 
Previous studies have suggested that disrupted Ca2+ homeostasis 
due to the absence of extracellular Ca2+ results in the loss of 
mitochondrial glutathione through an unknown mechanism. The goal 
of the present work is to further investigate the role of Ca2+ in regulating 
glutathione levels in isolated rat liver mitochondria. In particular, this 
work has explored the role of mitochondrial permeability transition in 
this process. 
We selected inorganic phosphate as the inducer of permeability 
transition. In the Ca2+ omission model of cellular oxidative stress, no 
exogenous treatment is needed, other than the removal of physiological 25 
Ca2+. The use of inorganic phosphate therefore seemed to possibly 
provide a mimic of the cellular model which was our initial goal. 
In summary, with this research we hoped to further characterize 
the role of mitochondrial glutathione and mitochondrial Ca2+ 
homeostasis and explore the mechanism(s) of how disrupted Ca2+ 
homeostasis influences electron transport processes, cellular energy 
production, and transport of GSH. The major questions addressed here 
were (1) Does Ca2+- and inorganic phosphate-induced permeability 
transition affect mitochondrial glutathione status? (2) Does opening of 
the Ca2+-dependent pore provide a mechanism to load mitochondria 
with glutathione? (3) What effect do respiratory inhibitors have on 
permeability transition and glutathione status? (4) What are the effects of 
Ca2+- and inorganic phosphate-induced permeability transition on 
mitochondrial pyridine nucleotides and adenine nucleotides? 26 
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III. CALCIUM- AND PHOSPHATE-DEPENDENT RELEASE AND
 
LOADING OF GLUTATHIONE BY LIVER MITOCHONDRIA 
Abstract 
The status of glutathione was studied in isolated rat liver mitochondria 
under conditions which induce a permeability transition. The transition 
is characterized by an increased inner membrane permeability to some low 
molecular weight solutes and by large amplitude swelling. Addition of 70 
11M Ca2+ and 3 mM Pi to mitochondria resulted in mitochondrial 
swelling and extensive release of glutathione that was recovered in the 
extramitochondrial medium as glutathione. Both swelling and the efflux 
of mitochondrial glutathione were prevented by CsA.  Incubation of 
mitochondria in the presence of Ca2+, Pi, and glutathione followed by the 
addition of CsA provided a mechanism to load mitochondria with 
exogenous glutathione that was greater than the rate of uptake by 
untreated mitochondria. Thus, glutathione efflux from  mitochondria 
may occur under toxicological and pathological conditions in which 
mitochondria are exposed to elevated Ca2+ in the presence of near 
physiological concentrations of Pi through a nonspecific pore. Opening 
and closing of the pore could also provide a mechanism for the uptake of 
glutathione by mitochondria. 42 
Introduction 
Isolated mitochondria from a variety of tissues can undergo a Ca2+ ­
dependent permeability transition (1-9). Previously identified 
characteristics of the transition include permeability of the inner 
mitochondrial membrane to several low molecular weight (<  1200 Da) 
solutes, loss of coupled functions, and large amplitude swelling (1-4). The 
transition occurs when mitochondria are treated with Ca2+ in the 
presence of an inducing agent. Several structurally and functionally 
different inducing agents have been identified.  Examples of inducing 
agents include near physiological concentrations (10) of inorganic 
phosphate (Pi) (4), hydroperoxides (2), some heavy metals (11), and 
sulfhydryl reagents (5). 
The increased permeability is thought to occur through a Ca2+ 
-dependent nonspecific inner membrane pore through which ions and 
small molecules can diffuse very quickly from the mitochondrial matrix 
(1-3). Cyclosporin A (CsA), an immunosuppressive cyclic peptide, is a 
potent inhibitor of the permeability transition and solute movement via 
this nonspecific pore (4, 12-13). In a recent report, Szabo' and Zoratti (14) 
suggested that the Ca2+-dependent pore of the permeability transition and 
the giant channel of the inner mitochondrial membrane as observed with 
patch clamp techniques are the same species. This suggestion is based on 
the common feature of inhibition by CsA. 
Rat liver mitochondria contain approximately 10 mM glutathione 
(307 Da) verses 7 mM glutathione in the cytosol (15-16).  The cytosolic 
glutathione pool may supply the mitochondrial glutathione pool via a 43 
specific transport system since glutathione synthesis has not been observed 
with mitochondria. Early studies by Jocelyn et al. (17) indicated that the 
retention of mitochondrial glutathione is a highly regulated process. This 
observation was based on the finding that isolated mitochondria retained 
their glutathione, indicating that under normal isolation conditions, the 
inner mitochondrial membrane is impermeable to glutathione (17). 
At present, very little is understood about the mechanism(s) of 
glutathione movement in isolated mitochondria or in mitochondria 
contained in cells. We therefore investigated the effect of the permeability 
transition on glutathione status in isolated rat liver mitochondria to 
determine if opening the pore provides a mechanism for glutathione 
release and uptake. 44 
Experimental Procedures 
Materials 
All chemicals were purchased from commercial sources and were of 
the highest quality available. CsA was a generous gift from Dr. Sue 
Kohlhepp (Providence Hospital, Portland, OR). CsA was dissolved in 
100% ethanol (0.5 mM stock) and stored at 4°C. [3H]H20 (2 mCi/m1), 
[14C]sucrose (0.5 mCi /ml), [35S]GSH (55.2 Ci/mol), and scintillation 
cocktail (formula 983) were purchased from New England Nuclear. 
Mitochondrial Preparation 
Liver mitochondria were isolated from 325-375 g male Sprague-
Dawley rats by the method of Schnaitman and Greenwalt (18) and washed 
twice in an isolation medium containing 220 mM mannitol, 70 mM 
sucrose, 2 mM HEPES, and 0.5 mg/ml bovine serum albumin (defatted), 
pH 7.0. Mitochondrial protein was measured by the method of Bradford 
(19) or Peterson (20) with bovine serum albumin as protein standard. 
Cytosolic contamination in the final mitochondrial suspension was 
negligible as determined by measuring the activity of the cytosolic enzyme, 
lactate dehydrogenase (21). The mitochondrial matrix enzyme, citrate 
synthase was determined to assess mitochondrial leakage (22). 
Mitochondrial Incubations 
Washed mitochondrial pellets were suspended in 5-7 ml of 
incubation medium containing 213 mM mannitol, 71 mM sucrose, 3 mM 
HEPES (Nat), 10 mM succinate (Nat), and 1[LM rotenone (0.5 mM stock 45 
dissolved in 100% ethanol). Mitochondria were suspended in 25 ml 
Erlenmeyer flasks at protein concentrations of 1 mg/ml. After making 
various additions to the buffer, initial time points were taken immediately 
following the addition of mitochondria. The ensuing mitochondrial 
suspensions were rotated (100 rpm) in a Lab-Line Orbit Environ-Shaker  at 
25°C and exposed to atmospheric air for the incubation period. 
Samples (1 ml), taken at the times indicated in the figure legends, 
were transferred to 1.5 ml microcentrifuge tubes and centrifuged for 30 s at 
13,000 g. The supernatants were removed for further biochemical 
analysis. The pellets were washed once in incubation buffer containing 
the treatment compounds. The washed mitochondria were suspended 
(and pelleted) in 0.2 ml 10% (w/v) perchloric acid (containing the internal 
standard, gamma-glutamyl-glutamate) for analysis of mitochondrial 
glutathione. 
Biochemical Analyses 
Both intra- and extramitochondrial glutathione and glutamate 
levels were determined by the HPLC method of Reed et al. (23). Briefly, 
supernatant and perchloric acid samples were derivatized for HPLC 
analysis by the addition of iodoacetic acid (20 mg/ml H2O containing 
cresol purple as a pH indicator) followed by 2,4-fluorodinitrobenzene (1% 
v/v in 100% ethanol). The derivatized samples were stored in the dark for 
24 hr at 4°C prior to HPLC analysis as previously described (23). 
Total intramitochondrial Ca2+ content was determined in the 10% 
perchloric acid mitochondrial extracts. Intramitochondrial samples were 
taken from the perchloric acid layer and mixed with an equal volume of 46 
0.1% LaC13 to inhibit interference by other ions and then analyzed for total 
intramitochondrial Ca2+ with a Perkin-Elmer model 403 atomic 
absorption spectrophotometer (acetylene and air). Inorganic phosphate 
was determined by the method of Fiske and Subbarow (24). Samples (1.0 
ml) were centrifuged at 13,000 g for 30 s and the pellets resuspended in 0.12 
ml 5% trichloroacetic acid. Samples were kept on ice prior to being 
assayed. 0.1 ml was transferred to a glass tube containing 0.7 ml 5% 
trichloroacetic acid. 0.2 ml acid molybdate (1.25 g ammonium molybdate 
in 100 ml of 2.5 N sulfuric acid) was added, followed by the addition of 0.05 
ml Fiske Subbarow reducer (Sigma). The solution was vortexed and the 
absorbance at 660 nm was determined with an Aminco DW 2000 
spectrophotometer following a 10 min incubation. 
Mitochondrial swelling was determined spectrophotometrically by 
monitoring the decrease in absorbance at 540 nm with an Aminco DW 
2000 spectrophotometer operated in split beam mode (25).  Mitochondrial 
volumes were determined using [3H]H2O and [14C]sucrose as described in 
earlier methods (26-27). These measurements are based on the 
assumptions that H2O is permeable to all mitochondrial  compartments 
and sucrose is permeable to only the outer membrane in normal 
mitochondria. The glutathione permeable space was determined with 
[35S]GSH. Briefly, mitochondria (1 mg protein/m1) were incubated in 25 
ml Erlenmeyer flask containing either [3H]1-120, [14C]sucrose, or [35S]GSH. 
For incubations with [35S]GSH, 1 mM cold glutathione was added to the 
incubation buffer. Aliquots (1 ml) were taken at the time points indicated 
in the figure legends and centrifuged immediately.  Supernatant samples 
(0.05 ml) were taken for scintillation counting on a Packard Liquid 47 
Scintillation Spectrometer (Model 2450). The pellet was washed 
immediately in appropriate buffer and then resuspended in 0.2 ml 10% 
perchloric acid. Following centrifugation, 0.1 ml samples were taken for 
scintillation counting. 48 
Results 
The permeability transition in isolated mitochondria is a well 
characterized Ca2+-dependent phenomenon that includes such changes as 
large amplitude swelling and movement of solutes from the 
mitochondrial matrix compartment, presumably due to permeability 
changes of the inner mitochondrial membrane. Figure III. 1 shows that 
mitochondria (1 mg/ml) treated with 70 I.LM Ca2+ and 3 mM Pi (Ca Pi) 
undergo a rapid loss in absorbance at 540 nm, consistent with 
mitochondrial swelling (25). Maximal swelling occurred within 4 min 
and was inhibited by treatment with 0.5 .tM CsA, a potent inhibitor of the 
Ca2±-dependent nonspecific pore (4, 12-13). CsA added between 0-4 min 
prevented further swelling from occurring, although mitochondrial 
absorbance did not recover to control values (data not shown). 
Swelling also occurred in mitochondria treated with 3 mM Pi alone 
(Figure III. 1), probably due to the presence of endogenous Ca2± (data 
shown below) that is retained or acquired during the isolation procedure. 
Addition of 1 mM EGTA, a Ca2+ chelator, in the presence of 3 mM Pi 
prevented mitochondrial swelling (data not shown), verifying the 
dependence of pore formation on the presence of Ca2+. 
During the permeability transition, some low molecular weight ions 
and molecules (<1200 Da) are released from the mitochondrial matrix (3). 
We therefore investigated the effect of the permeability transition on 
mitochondrial glutathione (307 Da). Figure III. 2 shows that treatment 
with Ca Pi resulted in extensive release of mitochondrial  glutathione 
within 5 min that was recovered in the extramitochondrial buffer as 49 
glutathione (Figure III. 2B). Measurement of citrate synthase  activity 
during the 30-min incubation showed that this matrix enzyme is retained, 
indicating that mitochondrial lysis could not account for the glutathione 
released. The addition of 0.5 uM CsA (at time zero) in the presence of Ca Pi 
treated mitochondria completely inhibited the release of glutathione 
(Figure III. 2A, B) suggesting that glutathione release occurred through the 
Ca2+-dependent pore. 
Treatment with 3 mM Pi alone also induced the permeability 
transition and resulted in extensive glutathione release (Figure III. 2A,B), 
with nearly complete loss from mitochondria occurring in 20 min. EGTA 
(1 mM) was added to determine if the presence of endogenous Ca2+ 
contributed to the release of glutathione under these conditions. Our 
findings showed that removal of Ca2+ by chelation prevented glutathione 
release (data not shown) as it also protected against mitochondrial 
swelling. 
We also examined the effects of 70 uM Ca2+ alone  on mitochondrial 
glutathione release (data not shown). During the 30 min incubation 
period, Ca2+- treated mitochondria underwent only slight swelling (less 
than 10% increase in volume) and released approximately 23% of their 
glutathione that was recovered in the incubation medium. This partial 
release of mitochondrial glutathione may be explained by the presence of 
endogenous Pi. 
Measurement of intramitochondrial Pi (Figure III. 3) showed that 
untreated (control) mitochondria contained about 5 nmoles Pi/mg 
protein. With the addition of 70 uM Ca2+, the mitochondrial Pi levels 
increased slightly over control values. With the addition of 3 mM Pi or 50 
Ca Pi, mitochondria accumulated nearly 6 and 8 times, respectively, the 
level of Pi retained by control mitochondria. For mitochondria treated 
with Ca Pi plus CsA, the Pi accumulation was nearly 15 times greater than 
control values and nearly twice the Pi concentration for CaPi treated 
mitochondria (Figure III. 3). The accumulation of Pi was a somewhat 
unexpected result, particularly for the Ca Pi-treated mitochondria. 
Mitochondria undergoing the permeability transition have been 
shown to lose matrix components such as Ca2+, Mg2+, and other solutes 
(1-3). We measured intramitochondrial Ca2+ to confirm these results 
(Figure III. 4) and our findings showed that Ca2+ is released rapidly by 
mitochondria undergoing the permeability transition.  The addition of 
CsA under these conditions prevented the loss of Ca2+.  Measurement of 
mitochondrial glutamate by HPLC showed qualitatively the same pattern 
of results as measurement of Ca2+ and glutathione, with complete loss of 
mitochondrial glutamate only occurring in mitochondria treated with 
Ca Pi (data not shown). 
Comparison of the extent of glutathione loss with the decrease in 
absorbance at 540 nm (swelling) showed that glutathione loss correlated 
with swelling for Ca2+ alone, Pi alone, and most of the data for Ca Pi 
(Figure III. 5). With Ca Pi, the swelling occurred so rapidly that the last 20­
30% of glutathione release occurred only as swelling approached 100%. 
Thus, the results indicate that rapid and complete loss of mitochondrial 
glutathione occurred under conditions where CaPi induced a permeability 
transition. 
Induction of the permeability transition has been shown to be 
associated with an increase in the sucrose permeable space. This is 51 
determined by incubating mitochondria with radiolabeled sucrose and 
comparing the amount of sucrose associated with the mitochondrial pellet 
following centrifugation (9, 28-29).  We performed similar experiments to 
compare the volume of sucrose-permeable space to the water-permeable 
space. Mitochondria were incubated with either [3H]H20 or [14C]sucrose 
and centrifuged through a layer of dibutylpthalate to separate intra- and 
extramitochondrial components. Our findings indicated that Ca Pi 
increased the sucrose-permeable space [from 2.49 ill/mg (± 0.391) to 4.62 
gl/mg (± 0.241)]. Addition of [35S]GSH instead of [14C]sucrose indicated 
that the glutathione permeable space is similarly increased [2.52 gl/mg (± 
0.138) to 5.35 1.11/mg (± 0.241)]. 
Addition of CsA to mitochondria that had undergone the 
permeability transition was found to result in blocking the further 
movement of sucrose (31). Thus, [14C]sucrose could be trapped in 
mitochondria by initially incubating with [14C]sucrose under conditions 
which caused the transition followed by addition of CsA to prevent 
further movement across the membrane. We performed similar 
experiments with [35S]GSH to determine whether glutathione could be 
similarly loaded or trapped into mitochondria. Addition of CsA to 
mitochondria following a brief incubation with Ca Pi and 1 mM exogenous 
glutathione provided a method to load exogenous glutathione that was 
not removed upon washing into the mitochondrial matrix (data not 
shown). 
Experiments to determine whether that increase in matrix 
glutathione was due to transport or to trapping by closing the pore were 
performed. The permeability transition was induced by incubation with 52 
Ca Pi in the presence of 1 mM glutathione and 0.3 12Ci/gmol [35S]GSH. 
CsA was added at either time zero or at the time the sample was taken for 
analysis (Figure III. 6). After centrifugation to remove the mitochondria 
from the incubation media, mitochondria were resuspended in the 
appropriate media without [35S]GSH and washed by recentrifugation. 
Using this protocol, only about 5% of the scintillation counts associated 
with the pellet could be attributed to counts in the extramitochondrial 
water as ascertained by measuring the amount of [3H]H20 remaining 
associated with the pellet following the same procedure. The amount of 
glutathione that was taken up by control mitochondria was about 0.5 nmol 
glutathione/min/mg protein (Figure III. 6). In the presence of Ca Pi, no 
time-dependent increase in glutathione was observed. However, addition 
of CsA to mitochondria undergoing the permeability transition resulted in 
a time-dependent increase in the amount of glutathione associated with 
the mitochondria. This amount was nearly twofold greater than the 
amount of glutathione transported by control mitochondria (Figure III. 6). 
Experiments in which CsA was added along with Ca Pi at zero time 
(permeability transition inhibited) showed somewhat less glutathione 
uptake than did mitochondria (control) without Ca Pi. Thus, the uptake of 
glutathione by transport systems under conditions which do not activate 
the pore or in which the pore is blocked was less than the uptake of 
glutathione by the controlled opening and closing of the pore. 53 
Discussion 
The present study provides evidence for a mechanism of both 
release and loading of mitochondrial glutathione. By inducing the 
permeability transition with Ca Pi mitochondria released nearly 100% of 
their glutathione within a 5 min incubation period. Addition of 3 mM Pi 
alone also induced the permeability transition, as indicated by 
mitochondrial swelling and nearly complete release of mitochondrial 
glutathione within 20 min. We hypothesize that release of matrix 
glutathione occurs through a Ca2+-dependent nonspecific pore which is 
opened during the transition, allowing movement of some low molecular 
weight molecules. CsA, an inhibitor of the pore, prevented loss of 
glutathione in the presence of either Pi alone or Ca Pi. Treatment with 
CsA provided a method to load mitochondria with exogenous glutathione 
by first inducing the transition, and then adding CsA to close or inhibit the 
pore. 
Since the function of the Ca Pi-dependent pore is not known, it is not 
clear whether activation of the pore is necessarily physiological or 
deleterious. In a recent report, Halestrap and Davidson (30) suggested that 
this pore is the adenine nucleotide transporter that has been converted to 
a different functional state by Ca2+ and Pi. They reported that CsA 
probably binds to the mitochondrial matrix enzyme, peptidyl-prolyl cis-
trans isomerase (PPI) and prevents the enzyme from interacting with the 
adenine nucleotide translocase. Their study suggested that the interaction 
of PPI with the adenine nucleotide translocase in the presence of Ca2+ and 
an inducing agent results in nonspecific pore opening. They further 54 
suggested that an occasional opening and closing of the pore could provide 
a mechanism for the mitochondria to eliminate waste products for which 
no specific transport system exists. Such an occasional opening and 
closing of the pore also could provide a means to load mitochondria with 
cytoplasmic components, including glutathione. We directly compared 
the amount of glutathione that was loaded with the pore closed verses the 
pore opened and found that the rate of loading was greater through the 
pore. However, it must be emphasized that sustained opening of the pore, 
such as would occur with a sustained elevation of Ca2+, is likely to cause 
extensive loss of mitochondrial components and result in irreversible 
damage. 
Our data indicated that the presence of a near physiological 
concentration of Pi (3 mM) is sufficient to induce the permeability 
transition. This is presumably due to the presence of 6-10 nmol Ca2+ per 
milligram of protein retained by the mitochondria during the isolation 
procedure. Whether this Ca2+ is free or bound remains to be determined. 
However, by chelating the Ca2+ with the addition of 1 mM EGTA, 
mitochondria' swelling and glutathione release were both prevented, 
indicating the dependence of pore formation on the presence of available 
Ca2+. The presence of 70 p.M Ca2+ (alone) did not result in any 
appreciable swelling; however, these mitochondria released approximately 
23% of their glutathione. 
Control mitochondria contained about 5 nmol Pi/mg protein while 
Ca2+ treated mitochondria nearly doubled their Pi concentration. The 
increased levels of Pi may reflect ATP hydrolysis since the uptake of Ca2+ 55 
via the uniport is an energy dependent process that can lead to dissipation 
of the mitochondrial membrane potential. 
Ca2+ and other matrix components measured (glutathione and 
glutamate) were released when mitochondria were treated with Ca Pi. 
However, Pi was unexpectedly retained within the matrix under 
conditions which induced the permeability transition. Possible 
explanations for Pi retention include formation of a phosphate precipitate 
or interaction of Pi with molecules that are retained within the matrix 
under these conditions. Such interactions may include ionic or covalent 
association of Pi with molecules such as protein(s) retained within the 
matrix compartment. 
Pi retention raises the question of whether the Ca2+-dependent pore 
has some selectivity. To our knowledge, this is the first evidence that 
raises the question of selectivity of the Ca2+-dependent pore. Previous 
findings suggests that the pore is nonspecific due to the variety of 
molecules and ions which are permeable. 
In summary, the present study demonstrates a Ca2+-dependent 
mechanism for the rapid and nearly complete release of mitochondrial 
glutathione. Evidence presented suggests that the release of matrix 
glutathione occurs through a Ca2+-dependent pore of which CsA is a 
potent inhibitor. The addition of CsA prevented glutathione release as 
well as mitochondrial swelling.  Understanding how CsA prevents 
permeability changes and consequently release of matrix solutes may 
provide mechanistic insight as to how this type of mitochondrial response 
occurs. In addition we have shown that glutathione can also be trapped or 56 
loaded in mitochondria by opening and closing of the pore with Ca Pi and 
CsA respectively. _____ 
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Figure III. 1. Mitochondrial swelling. Mitochondrial suspensions (1
mg/ml) were monitored continuously for 30 min at absorbance 540 nm 
using a Aminco DW 2000 spectrophotometer in split beam mode in the
presence of treatments listed. Values are from a single representative
experiment. 58 
Figure III. 2. The effect of permeability transition on mitochondrial 
glutathione. Mitochondria (1 mg/ml) were incubated in the absence 
(control) or presence of 70 11M Ca2+ + 3mM Pi (Ca Pi); 3 mM Pi (Pi); or 
70 0/1 Ca2+ + 3 mM Pi + 0.5 .tM CsA (CaPiCsA) for 30 min.  Samples (1
ml) were taken at the various times indicated and analyzed for (A) intra­
and (B) extramitochondrial glutathione as described in Experimental
Procedures. Values are expressed as means of nmol glutathione per mg 
mitochondrial protein ± S.E.M. n = 4. 59 
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Figure III. 3. Mitochondrial inorganic phosphate concentrations.  Pi levels 
were determined in mitochondria incubated in the absence (control, 
closed square) or presence of 70 p.M Ca2+ (closed circle);  3 mM Pi 
(diamond); 70 11M Ca2+ + 3 mM Pi (open square); or 70 1.tM Ca2+ + 3 mM 
Pi + 0.5 1AM CsA (open circle). Samples (1 ml) were assayed for Pi at the
various times indicated as described in Experimental Procedures.  Values 
are expressed as means ± S.E.M. n = 4. 61 
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Figure III. 4. Total intramitochondrial Ca2+ concentrations. Ca2+ levels 
were determined in the absence (control) or presence of 70 pM Ca2+ + 3 
mM Pi (Ca Pi); 3 mM Pi (Pi); or 70 pM Ca2+ + 3 mM Pi + 0.5 p,M CsA 
(CaPiCsA). Samples (1 ml) were taken at the various times indicated and 
analyzed for total intramitochondrial Ca2+ as described in Experimental 
Procedures. Values are expressed as means ± S.E.M. n = 4. 62 
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Figure III. 5. Correlation of mitochondrial swelling and glutathione loss. 
Data are expressed as percent mitochondrial glutathione loss vs percent 
mitochondrial swelling in the presence of either 7011M Ca2+(circle); 3 mM 
Pi (diamond); or 70 1.1M Ca2+ + 3 mM Pi (square). Mitochondrial samples 
were analyzed at 5, 10, and 15 min for both swelling and GSH loss. For 
each treatment, the earliest time point correlates with the least amount of 
swelling and GSH loss whereas the latest time point correlates with the 
greatest amount of swelling and GSH loss. Data are derived from the 
average of 2 representative experiments. 63 
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Figure III. 6. Effect of the permeability transition on mitochondrial 
glutathione uptake. Mitochondria (1 mg/ml) were incubated with 1 mM 
glutathione + 0.3 pCi/gmol 35S-glutathione (control, closed square) in the 
presence of 70 iiM Ca2+ + 3 mM Pi (permeability transition induced, open 
square); or 70 11M Ca2+ + 3 mM Pi + 0.5 11M CsA (permeability transition 
inhibited, closed circle). To trap glutathione in mitochondria undergoing 
the permeability transition, 0.5 IIM CsA (open triangle) was added when 
the sample was taken for analysis as described in Experimental Procedures. 
Values are expressed as means ± S.E.M. n = 3. 64 
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IV. MITOCHONDRIAL GLUTATHIONE AND CACLIUM RELEASE
 
BY A CYCLOSPORIN A-SENSITIVE MECHANISM OCCURS
 
WITHOUT LARGE AMPLITUDE SWELLING
 
Abstract 
Treatment of isolated mitochondria with calcium and inorganic 
phosphate induces inner membrane permeability that is thought to be 
mediated through a nonselective, calcium-dependent pore. The inner 
membrane permeability results in the rapid escape of small matrix 
solutes such as glutathione and calcium, loss of coupled functions, and 
large amplitude swelling. In the current study, we have identified 
conditions of permeability transition without large amplitude swelling, 
a parameter often used to assess inner membrane permeability. The 
addition of oligomycin, antimycin, or sulfide to incubation buffer 
containing calcium and inorganic phosphate abolished large amplitude 
swelling, but did not prevent inner membrane permeability as 
demonstrated by the release of glutathione and calcium.  Release of 
both glutathione and calcium were inhibited by the addition of 
cyclosporin A, a potent inhibitor of permeability transition. 
Transmission electron microscopy (TEM) analysis, combined with 
biochemical data, indicate that permeability transition can be observed 
in the absence of large amplitude swelling. Collapse of the membrane 
potential was observed both with and without large amplitude 
swelling. We conclude that CsA-sensitive permeability transition can 
occur without obvious morphological changes and, therefore, that 68 
monitoring of the CsA-sensitive release of endogenous matrix solutes, 
such as GSH, may be a sensitive and useful indicator of permeability 
transition. 69 
Introduction 
Mitochondrial glutathione (GSH) is critical to cell viability, 
especially under experimental conditions involving a disruption of 
cellular Ca2+ homeostasis (1-5). These studies demonstrate a direct 
relationship between the loss in mitochondrial GSH and a decrease in 
cell viability; however, the mechanism by which GSH depletion occurs 
remains uncertain. 
Only 10-15% of the cellular GSH resides in liver mitochondria, 
where it is concentrated (10 mM vs. 7 mM in the cytosol) (13) and 
functions in cellular defense against reactive oxygen species, 
particularly H202 (14-15). Endogenous production of reactive oxygen 
species normally occurs during aerobic respiration, when 
approximately 4% of the 02 consumption results in the formation of 
H202 (14-15). Since liver mitochondria do not contain catalase (16), 
detoxification of H202 occurs through the GSH peroxidase/reductase 
redox cycle (17-18). Loss of mitochondrial GSH could therefore be 
detrimental to cell viability, particularly if challenged oxidatively. 
We have previously demonstrated a Ca2+ dependent 
mechanism for the rapid and nearly complete depletion of 
mitochondrial GSH (6). Treatment of isolated mitochondria with Ca2+ 
and Pi permeabilizes the inner membrane of mitochondria, releasing 
small matrix solutes such as GSH and Ca2+ (6-10). Permeability 
transition is thought to occur due to activation, or perhaps 
deregulation, an inner membrane protein that functions  as a putative 
pore. Following permeabilization, mitochondria undergo large 70 
amplitude swelling. Both inner membrane permeability and swelling 
are prevented by nanomolar concentrations of the 
immunosuppressive cyclic peptide, cyclosporin A (CsA) (6-7, 11-12). 
The transport of Ca2+ by mitochondria is driven by the 
transmembrane potential (19-21). The inward movement of Ca2+ 
decreases the transmembrane potential which is restored either by 
increasing respiratory chain activity or ATP hydrolysis. Since 
mitochondrial Ca2+ uptake is closely linked with permeability 
transition, we have decided to examine the effects of treatment with 
the metabolic inhibitors, antimycin, oligomycin, and sulfide, on inner 
membrane permeability, large amplitude swelling, and the 
transmembrane potential. Antimycin A and sulfide are electron 
transport inhibitors at complex III and cytochrome oxidase, 
respectively. Oligomycin inhibits ATP synthase and eventually stops 
all electron transport by coupled mitochondria.  (22) 
As discussed below, our findings indicate that Ca2+- and Pi-
dependent permeability transition can occur without large amplitude 
swelling in the presence of antimycin, sulfide, or oligomycin. These 
findings suggest that under certain experimental conditions assessment 
of mitochondrial integrity via the light scatter assay or TEM analysis 
may not accurately reflect the biochemical alterations due to changes in 
mitochondrial inner membrane permeability.  This information may 
be relevant to cellular or isolated mitochondrial studies relying on 
TEM for assessment of mitochondrial integrity, or studies of isolated 
mitochondria relying on the light scatter assay as a gauge of inner 
membrane permeability. 71 
Experimental Procedures 
Materials 
All chemicals were purchased from commercial sources and 
were of the highest quality available. CsA was a generous gift from Dr. 
Sue Kohlhepp (Providence Hospital, Portland, OR).  CsA was dissolved 
in 100% ethanol (0.5 mM stock) and stored at 4°C.  Oligomycin (A,B,C), 
antimycin A, and sodium sulfide were purchased from Sigma 
Chemical Company (St. Louis, MO). Aqueous stock solutions of 
sodium sulfide (0.5 M) were prepared the day of each experiment. Stock 
solutions of oligomycin (3 mM) and antimycin (1 mM) were dissolved 
in ethanol. [3H]TPMP (triphenylmethylphosphonium) (1mCi/m1) and 
scintillation cocktail (Formula 983) were purchased from New England 
Nuclear. 
Preparation of Mitochondria 
Isolated mitochondria were prepared by differential 
centrifugation according to the method of Schnaitman and Greenwalt 
(23). Briefly, livers from male Sprague-Dawley rats (325-375 g) 
(Simonsen Labs, Gilroy, CA) were excised and homogenized in 
isolation buffer containing 220 mM mannitol, 70 mM sucrose, 2 mM 
HEPES, 0.5 mM EGTA, and 0.5 mg/ml bovine serum albumin, pH 7.4. 
Mitochondria were washed twice in isolation buffer devoid of EGTA, 
pH 7.0.  After the final wash, the mitochondrial pellets were 
suspended (25-30 mg/ml) in incubation buffer containing 213 mM 
mannitol, 71 mM sucrose, 10 mM succinate, and 3 mM HEPES, pH 7.0. 72 
Mitochondrial protein was determined spectrophotometrically by the 
method of Bradford (24) with bovine serum albumin as the standard. 
Mitochondrial Incubations 
Aliquots of suspended mitochondria were added to 10-m1 
Erlenmeyer flasks (1 mg protein/m1) containing incubation buffer plus 
the various treatments described in the figure legends. After briefly 
swirling the flask, 1.0 ml samples were taken immediately following 
the addition of mitochondria. These samples constitute the initial 
time points. Mitochondrial suspensions were exposed to atmospheric 
air throughout the remainder of the incubation period. Aliquants 
(1m1) of mitochondrial suspensions, taken at the times indicated in the 
figure legends, were transferred to 1.5-m1 microcentrifuge tubes and 
immediately centrifuged for 30 s at 13,000 g. The supernatants were 
removed for further biochemical analysis where indicated. The 
remaining mitochondrial pellet was resuspended in 10% perchloric 
acid (PCA) and analyzed for GSH, Ca2+, or [3H]TPMP as described 
below. 
Biochemical Analysis 
GSH was determined by HPLC analysis according to the method 
of Reed et al. (26) with modifications as described previously (6).  Ca2+ 
levels were quantitated by atomic absorption spectrophotometry as 
previously described (6). Assessment of the mitochondrial membrane 
potential was determined by uptake of [3H]TPMP (27). Briefly, 
[3H]TPMP was added to incubation flasks to produce a final specific 73 
activity of 9 pC/umol. Aliquots (1 ml) of the suspended mitochondria 
were transferred to 1.5 ml microcentrifuge tubes and centrifuged at 
13,000 g for 30 s. The supernatant was discarded and the pellet 
carefully resuspended in incubation buffer devoid of [3H]TPMP and 
centrifuged to remove any remaining extramitochondrial [3H]TPMP. 
The final pellet was resuspended in 200 pl of 10% PCA, centrifuged, 
and prepared for scintillation counting on a Packard liquid scintillation 
spectrophotometer (Model 2450). 
Large amplitude swelling was assessed spectrophotmetrically by 
monitoring the decrease in absorbance at 540 nm with an Aminco DW 
2000 spectrophotometer operated in split beam mode (25). 
Concentration response to each metabolic inhibitor was established on 
the basis of the effect on swelling. 
TEM Analysis 
Samples (1 mg) for TEM were fixed in 3.0% glutaraldehyde, pH 
7.2, for approximately 4 hrs. Mitochondria were allowed to settle out by 
gravity and rinsed twice with 0.2M sodium cacodylate buffer.  The 
rinsed samples were centrifuged at 12,500  g for 10 min. Following 
centrifugation, the pellet was gently removed and minced into pieces, 1 
mm3. Samples were postfixed in 1.0% 0s04 for 1 hr, rinsed through a 
graded acetone series, infiltrated with, and embedded in, epoxy resin. 
Ultrathin sections (60-80 nm) were cut and stained with uranyl acetate 
and bismuth subnitrate. Specimens were examined with a Ziess EM 
10/A transmission electron microscope at an accelerating voltage of 60 
kV. 74 
Results 
Effect of Metabolic Inhibitors on Mitochondrial Large Amplitude 
Swelling, GSH, and CaLL 
Incubation of mitochondria with 70 i.tM Ca2+ and 3 mM Pi 
(Ca Pi) resulted in the rapid decrease in absorbance at 540 nm due to 
large amplitude swelling (Figure IV. 1E). Addition of 0.5 IIM CsA, a 
potent inhibitor of permeability transition, prevented large amplitude 
swelling induced by Ca Pi, appearing similar to untreated control 
samples (Figure IV. 1A) (6-7). Similarly, addition of either 0.5 mM 
sulfide, 3 1AM oligomycin, or 1 11M antimycin also inhibited Ca Pi 
induced large amplitude swelling that is generally associated with 
permeability transition (Figure IV. 1B,C,D). 
Mitochondria treated with Ca Pi undergo a rapid and nearly 
complete release of GSH within 5-min as previously demonstrated (6), 
and as shown in Figure IV. 2. The addition of either 0.5 mM sulfide, 3 
11M oligomycin, or 1 11M antimycin ameliorates Ca Pi induced loss  of 
matrix glutathione to varying degrees (Figure IV. 2). Sulfide and 
oligomycin are the most potent inhibitors of GSH loss within the first 
10-min of incubation, with antimycin being the weakest. 
The GSH was recovered in the extramitochondrial buffer as GSH 
(data not shown) which was prevented following the addition of 0.5 
11M CsA (Figure IV. 3). Detection of oxidized GSH (GSSG) did not occur 
above untreated control values (<0.5 nmol GSH equivalent/mg)  (Data 
not shown). The degree to which the compounds inhibit Ca Pi-induced 75 
GSH loss through a concentration dependent manner was not 
examined. 
Treatment of mitochondria with the electron transport 
inhibitors antimycin or sulfide decreases the membrane potential 
which drives Ca2+ ions into the mitochondria via the Ca2+ uniport. 
Diminished Ca2+ uptake corresponds to treatment with electron 
transport inhibitors. This is shown in Figure IV. 4, where in the 
presence of Ca Pi plus 0.5 mM sulfide or 1µM antimycin, uptake of 
Ca2+ is reduced approximately 65% as compared to mitochondria 
treated with Ca Pi alone. Mitochondria treated with 3 11M oligomycin 
(Figure IV. 4), an inhibitor of ATP synthesis, show an initial uptake of 
Ca2+ greater than Ca Pi alone. The increased uptake of Ca2+ is 
presumably due to the initial overshoot of the membrane potential 
because of inhibition of proton translocation at the ATP-synthase. 
After initially taking up Ca2+, mitochondria treated with Ca Pi 
alone rapidly released Ca2+ through a CsA-sensitive mechanism as 
previously reported and demonstrated in Figure IV. 4 (6). Regardless of 
the initial Ca2+ uptake in the presence of the metabolic inhibitors, 
Ca2+ are gradually released to levels similar to that observed with Ca Pi 
treatment alone (Figure IV. 4). Release of Ca2+ is prevented following 
the addition of 0.5 1.1M CsA (data not shown). 
TEM Analysis 
Since large amplitude swelling was not observed in the presence 
of metabolic inhibitors (Figure IV. 1), mitochondria were prepared and 
analyzed by TEM to determine if ultrastructural changes could be 76 
observed under these conditions. Figure IV. 5A shows untreated 
mitochondria following a 10-min incubation. They have an electron-
dense and well defined ultrastructure, indicating they are functionally 
and structurally intact and highly energized (28). 
Figure IV. 5B shows mitochondria undergoing permeability 
transition following a 5-min incubation in the presence of Ca Pi. A 
major proportion of the population has undergone large amplitude 
swelling as evidenced by the loss in electron density and an increase in 
size. By 10-min (Figure IV. 5C), nearly the entire population of 
mitochondria has undergone large amplitude swelling. Addition of 0.5 
11M CsA prevented the Ca Pi induced response as shown in Figure IV. 
5D following a 20-min incubation. 
Mitochondrial samples treated for 10-min with Ca Pi plus either 
0.5 mM sulfide, 3µM oligomycin, or 1 [EM antimycin, (Figure IV. 
5E,F,G, respectively,) do not exhibit morphological changes to the 
degree observed with Ca Pi treatment alone following a 5- or 10-min 
incubation (Figure IV. 5B,C). However, some mitochondria in these 
populations appear somewhat less electron dense than untreated 
mitochondria (Figure IV. 5A), and are perhaps in the orthodox 
conformation as opposed to the condensed conformation. These two 
conformations have been studied by Hackenbrock (28) who has 
proposed that they are related to either the metabolic state of the 
mitochondria, or the energization of the inner mitochondrial 
membrane. 
To determine if a correlation exists between GSH release and the 
morphological alterations observed with TEM analysis, these 77 
parameters were compared with the various treatment regimens. The 
degree of morphological alteration was assessed by counting, in 
random areas (2" X 2") of the electron micrographs, the number of 
morphologically altered mitochondria, and dividing this number by 
the total mitochondria within the area. Criteria used to identify altered 
mitochondria were loss of matrix density, enlargement (swelling), and 
similarity to mitochondria treated with Ca Pi (Figure IV. 5B,C). As 
shown in Table 1, the degree of morphological alteration does not 
correlate well with the amount of GSH released (correlation coefficient 
= 0.70). 
Finally, to assess mitochondrial energy status, the membrane 
potential was assayed by the uptake and retention of the radiolabeled 
lipophilic cation, f3H)TPMP. As shown in Figure IV. 6, the membrane 
potential was depleted almost immediately following Ca Pi treatment 
alone, or Ca Pi plus either 0.5 mM sulfide, li.tM antimycin, or 3 1.t.M 
oligomycin. A stable membrane potential, similar to that observed 
with untreated samples, was observed following the addition of 0.5 [IM 
CsA to Ca Pi-treated mitochondria in spite of high matrix Ca2+ levels 
(70 nmols Ca211mg protein) (6). 78 
Discussion 
The major findings of this report is the dissociation of inner 
membrane permeability from large amplitude swelling. As large 
amplitude swelling results from the permeabilization of the inner 
membrane, it is often used to assess whether permeability transition is 
occurring in mitochondrial samples. As a secondary event to 
permeability transition, large amplitude swelling occurs because matrix 
proteins are slow to equilibrate through the permeability defect as 
compared with smaller solutes. This is thought to create a colloid-
osmotic pressure imbalance which drives the entrance of water, 
resulting in dilution of the matrix and massive swelling (9). 
Several previous reports have suggested that both antimycin 
and oligomycin inhibit permeability transition (29-32). These 
conclusions are based upon the ability of these compounds to prevent 
large amplitude swelling. In this report, we have demonstrated the 
release of both matrix GSH and Ca2+ without large amplitude swelling. 
This occurs when either antimycin, oligomycin, or sulfide are 
coincubated in buffer containing Ca Pi (Figure IV. 1,2,4).  Under these 
conditions, the addition of CsA completely prevented GSH release 
(Figure IV. 3), as well as Ca2+ release (data not shown). Protection by 
CsA, a potent inhibitor of the permeability transition, suggests that 
inner membrane permeability occurs in the absence of large amplitude 
swelling. 
Analysis of mitochondrial samples by TEM also indicated that 
the morphological alterations observed with Ca Pi treatment are 79 
prevented when metabolic inhibitors are present, yet biochemically, 
these systems are similar as reflected by the loss of matrix solutes. 
These findings suggest that severe mitochondrial injury, such as the 
loss of matrix GSH, can occur without obvious morphological changes. 
Therefore, it may be necessary to monitor solute release rather than 
relying solely on ultrastructural analysis such as TEM or the decrease in 
light scatter at 540 nm to assess inner membrane permeability. 
Whether inner membrane permeability occurs only in a 
susceptible subpopulation or gradually throughout the entire 
population is not clear. If a susceptible subpopulation exists, then the 
release of matrix solutes (GSH and Ca2+) presumably represents release 
of GSH and Ca2+ from the susceptible population and would most 
likely be accompanied by large amplitude swelling.  However, a 
comparison of the percent of GSH released with the percent of 
mitochondria exhibiting morphological alterations does not seem to 
strongly support this argument. Following a 10-min incubation, 
mitochondria coincubated with Ca Pi plus either antimycin, 
oligomycin, or sulfide, released 73%, 65%, and 27%, respectively, of 
their GSH. Seemingly, if this were an all-or-none response, then the 
percent of GSH released would represent the total release of GSH from 
73%, 65%, and 27% of the mitochondrial population, and some 
comparable degree of large amplitude swelling would be observed. 
Since the degree of morphological alterations does  not correlate 
strongly with the degree of GSH released (Table 1), low inner 
membrane permeability may be occurring throughout the population. 
Although mitochondria do not appear altered morphologically, they 80 
may be experiencing some degree of permeability barrier disruption. 
Release of Ca2+ appears to occur from the entire population, as 
opposed to a subpopulation, as near maximal Ca2+ release occurred 
following treatment with the metabolic inhibitors (Figure IV. 4). 
Mitochondria treated with oligomycin, antimycin, or sulfide in 
buffer containing Ca Pi appear to be in the orthodox conformation as 
opposed to the condensed (Figure IV. 5E,F,G) (28). Changes in 
morphology from the condensed to the orthodox conformation  are 
generally associated with a decrease in mitochondrial energy status (28). 
Mitochondrial energy status is regulated by several different 
parameters including membrane potential, adenine nucleotides, 
pyridine nucleotides, the ratio of GSH:GSSG as well as the ratio of total 
thiols:total disulfides.  Recent publications (33-34) suggest that the 
collapse of the membrane potential is the likely cause of permeability 
transition. Other studies have also suggested that membrane potential 
is important in regulating inner membrane permeability (35-37). 
We assessed the membrane potential under the various 
conditions studied by measuring the uptake and retention of the 
radiolabeled lipophilic cation, [3H]TPMP, which is directly related to 
the membrane potential (27). As shown in Figure IV. 6, exposure of 
mitochondria to Ca Pi resulted in an immediate 80% decrease in TPMP 
uptake that was prevented by CsA. Addition of CsA preserved the 
membrane potential similarly to untreated samples throughout a 20­
min incubation, although these samples contain a high level of matrix 
Ca2+ (6). 81 
Although the addition of the metabolic inhibitors to Ca Pi treated 
mitochondria prevented mitochondrial large amplitude  swelling, and 
inhibited solute release to varying degrees, they did not prevent the 
collapse of the membrane potential. By the initial time point, the 
membrane potential had collapsed and remained so throughout the 20­
min incubation. 
The addition of antimycin or sulfide alone (without Ca Pi) to 
mitochondrial suspensions also resulted in the immediate collapse of 
the membrane potential (data not shown).  However, treatment with 
sulfide or antimycin alone did not result in the release of GSH, nor 
were there any other indications of permeability transition. Addition 
of oligomycin alone did not collapse the membrane potential during 
the 20-min incubation (data not shown). 
One possible interpretation of these results is that the collapse of 
the membrane potential alone may not result in permeability 
transition but may require other biochemical factor(s)  or conditions as 
yet unidentified. Loss of the membrane potential  appears to 
accompany the permeable state, but does not correlate with whether or 
not large amplitude swelling occurs. These findings suggest that 
collapse of the membrane potential accompanies and/or contributes to 
the inner membrane permeability but may not provide the sole trigger 
for the transition to the permeable state. The permeability transition 
may be regulated by several different events, and depending upon 
which have occurred, these may determine the severity of inner 
membrane permeability. 82 
Schlogel et al. (38) recently reported that t-butylhydroperoxide 
induced Ca2+ release in mitochondria was due to the hydrolysis of 
NAD+ and subsequent mono-ADP ribosylation of a critical protein that 
allows the specific release of Ca2+; however, this release was not 
accompanied by mitochondrial swelling. It is tempting to speculate 
that the release of mitochondrial Ca2+ (38) may have occurred via a 
mechanism similar to the one we report here. The status of matrix 
components, such as GSH, were not reported in their study (38). 
In summary, our major findings suggest that the absence of 
mitochondrial large amplitude swelling does not indicate an absence of 
an inner membrane permeability. We find that CsA-sensitive 
permeability transition can occur without large amplitude swelling, 
and that under these conditions, the loss of solute regulation of GSH 
and Ca2+ is indicated by the release of these molecules. Ultrastructural 
analysis of mitochondria by TEM, or monitoring of mitochondrial 
swelling spectrophotometrically at 540 nm, did not indicate the 
significant biochemical alterations occurring under the conditions 
studied. This observation maybe important because mitochondrial 
integrity is often assessed by TEM and the light scatter assay. We 
conclude that CsA-sensitive permeability transition can occur without 
obvious morphological changes. Therefore, monitoring the CsA­
sensitive release of endogenous matrix solutes, such as GSH, may be a 
sensitive and useful indicator of permeability transition. 83 
Table IV. 1. Comparison of Morphological Alterations and GSH Release * 
% Morphological  %GSH Release  r=0.700 
Alterations** 
Control  6.75  0 
Ca Pi  100  95 
+CsA  0  0 
+Sulfide  18.5  27 
+ Oligomycin  10.5  65 
+Antimycin  14.5  73 
*Data analyzed following a 10-min incubation under the various 
incubation conditions as previously described. Control  = untreated 
mitochondrial samples; Ca Pi = 70 1AM Ca2+ and 3 mM Pi; 
+CsA = 0.5 I.LM CsA plus Ca Pi; +sulfide = 0.5 mM sulfide plus Ca Pi; 
+oligomycin = 3 11M oligomycin plus Ca Pi; and +antimycin = 11.tM
 
antimycin plus Ca Pi.
 
**The percent of mitochondria with morphological alterations was
 
calculated by counting, in random areas (2" X 2") on the electron

micrographs, the number of morphologically altered mitochondria,
 
and dividing this number by the total mitochondria within the area.
 
Criteria used to identify altered mitochondria were a loss of matrix
 
density, enlargement (swelling), and similarity to mitochondria
 
treated with Ca Pi.
 
***r=correlation coefficient calculated by linear regression analysis.
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Figure IV. 1. Mitochondrial Swelling. Mitochondrial suspensions 
(1mg/m1) were monitored continuously for 20 min using an Aminco 
DW 2000 spectrophotometer. Traces A-E are representative of the 
following treatments; A. control or 70 RINA Ca and 3 mM Pi (CaPi) plus 
0.5 liM CsA; B. 0.5 mM sulfide CaPi; C. 1 1.tM antimycin plus CaPi; D. 
3 IAM oligomycin plus CaPi; E. CaPi. 85 
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Figure IV. 2. Mitochondrial glutathione concentrations. Mitochondria 
(1mg/m1) were incubated in the absence (control) or presence of either 70 
1,IM Ca2+ and 3 mM Pi (Ca Pi); 0.5 mM sulfide plus Ca Pi; 3 i.tM 
oligomycin plus Ca Pi; 1 I.LM antimycin plus Ca Pi. Samples (1 ml) were 
taken at the various times indicated and analyzed for GSH as described in 
Experimental Procedures. n=3-4 ± S.E.M. 86 
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Figure IV. 3. Protection with cyclosporin A against glutathione release. 
Mitochondria (1mg/m1) were incubated in the presence of either 0.5 mM 
sulfide plus 70 .tM Ca2+ and 3 mM Pi  plus 0.5 g CsA (CaPiCsA), 3 11M
oligomycin plus CaPiCsA or 1 p.M antimycin plus CaPiCsA. Samples (1 ml) 
were taken at the various times indicated and analyzed for GSH as described 
in Experimental Procedures. n = 3-4 ± S.E.M. 87 
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Figure IV. 4. Calcium status following treatment with metabolic 
inhibitors. Mitochondria (1mg/m1) were incubated in the absence 
(controls) or presence of either 70 j.tM Ca2+ and 3 mM Pi (Ca Pi); 0.5 mM 
sulfide plus Ca Pi;  3 11M oligomycin plus Ca Pi; 1 1.1M antimycin plus 
Ca Pi.  Samples (1 ml) were taken at the various times indicated and 
analyzed for Ca2+ as described in Experimental Procedures. n = 3-4 ± 
S.E.M. 88 
Figure IV. 5. Ultrastructure of mitochondria in the absence and 
presence of metabolic inhibitors during permeability transition. 
Mitochondria (1mg/m1) were prepared for TEM as described in 
Experimental Procedures. (A) Control (untreated) mitochondria 
following a 10-min incubation; (B) Mitochondria incubated with 70 
1.1M Ca2+ and 3 mM Pi (Ca Pi) for 5 min; (C) Mitochondria incubated 
with Ca Pi for 10 min; (D) Mitochondria incubated with Ca Pi plus 0.5 
1.1M CsA for 20 min; (E) Mitochondria incubated with Ca Pi plus 0.5 
mM sulfide for 10 min; (F) Mitochondria incubated with Ca Pi plus 3 
oligomycin for 10 min; (G) Mitochondria incubated with Ca Pi plus 
1p,M antimycin for 10 min. 91 
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Figure IV. 6. Uptake of the cationic compound [3H]TPMP 
(triphenylmethylphosphonium): assessment of the mitochondrial
membrane potential. Mitochondria were incubated in the presence or 
absence of the various treatments with the addition of [3H]TPMP. Samples 
were taken at the times indicated and prepared for analysis by liquid 
scintillation counting as described in the Experimental Procedures. 
n = 3 ± S.E.M. 97 
References 
1.	  Olafsdottir, K., Pascoe, G., and Reed, D.J. (1988) Arch. Biochem. 
Biophys. 263: 226-235. 
2.	  Meredith, M.K. and Reed, D.J. (1983) Biochem. Pharm. 32: 1383­
1388. 
3.	  Meredith, M. J. and Reed, D.J. (1982) J. Biol. Chem. 257: 3747­
3753. 
4.	  Thomas, C.E, and Reed, D.J. (1988) J. Pharm. Exp. Ther. 245: 
493-500. 
5.	  Thomas, C.E, and Reed, D.J. (1988) J. Pharm. Exp. Ther. 245: 
501-507. 
6.	  Savage, M.K., Jones, D.P., and Reed, D.J. (1991) Arch. Biochem. 
Biophys. 290: 51-56. 
7.	  Broekemeier, K.M., Dempsey, M.E., and Pfeiffer, D.R. (1989) J. 
Biol.  Chem. 264: 7826-7830. 
8.	  Crompton, M. and Costi, A. (1990) Biochem. J. 266: 33-39. 
9.	  Gunter, T.E. and Pfeiffer, D.R. (1990) Am. J. Physiol. 258. C755­
C786. 
10.	  Halestrap, A.P., Griffiths, E1J. and Connern, C.P. (1993) Biochem. 
Soc. Trans. 21. 353-358. 
11.	  Crompton, M., Ellinger, H., and Costi, A. (1988) Biochem. J. 255: 
357-360. 
12.	  Fournier, N., Ducet, G., and Crevat, A. (1987) J. Bioenerg. 
Biomembr. 19: 297-303. 
13.	  Wahllander, A., Soboll, S., and Sies, H. (1979) Febs. Letts. 97: 
138-140. 
14.	  Chance, B., Sies, H., and Boveris, A. (1979) Phys. Rev. 59: 527­
605. 98 
15.	  Cadenas, E. Biochemistry of Oxygen Toxicity. (1989)  Annu. Rev. 
Biochem. 58: 79-110. 
16.	  Neubert, D., Wojtszak, A.B., and Lehninger, A.L. (1962)  Proc.
 
Natl. Acad. Sci., USA, 48: 1651-1658.
 
17.	  Beutler, E. in "Glutathione: Proceedings on the 16th Conference 
of the German Society of Biological Chemistry, Tubingen, March
1973" (1974) Eds. Flohe, L., Benohr, H., Sies, H., Waller, H.D.,
and Wendel, A. 
18.	  Flohe, L. and Gunzler, W.A. in "Glutathione:  Proceedings on

the 16th Conference of the German Society of Biological
 
Chemistry, Tubingen, March 1973" (1974) Eds. Flohe, L.,
 
Benohr, H., Sies, H., Waller, H.D., and Wendel, A.
 
19.	  Becker, G.L., Fiskum, G., and Lehninger, A.L. (1980) J. Biol.
 
Chem. 255: 9009-9015.
 
20.	  Denton, R.M. and McCormack, J.G. (1988)  Biochem Soc. Trans. 
16: 523-527, 1988. 
21.	  Rossi, C.S. and Lehninger, A.L. (1964) J. Biol. Chem. 239: 3971­
3980.
 
22.	  International Encyclopedia of Pharmacology and Therapeutics,
Section 107 "Inhibitors of Mitochondrial Function"  (1981) Eds.
Erecinska, M., and Wilson, D.F., Pergamon, Press. 
23.	  Schnaitman, C., and Greenwalt, J.W. (1968)  J. Cell. Biol. 38: 158­
175. 
24.	  Bradford, M. (1976) Anal. Biochem. 72:  248-254. 
25.	  Lehninger, A. (1962) Physiol. Rev. 42:  467-517. 
26.	  Reed, D.J., Babson, J.R., Beatty, P.W., Brodie, A.B., Ellis, W.W., 
and Potter, D.W. (1980) Anal. Biochem.  106: 55-62. 
27.	  Dawson, A., Klingenberg,M., and Kramer, R.  in "Mitochondria, 
A Practical Approach." (1987) Eds. Darley-Usmar, V.M., 
Rickwood, D. and Wilson, M.T., IRL Press. 99 
28.	  Hackenbrock, C.R. (1968) J. Cell. Biol. 37: 345. 
29.	  Pfeiffer, D.R., Kuo, T.H., and Chen, T.T. (1976) Arch. Biochem. 
Biophys. 176: 556-563. 
30.	  Le-Qiloc, D. and Le-Qiioc, K. (1989) Arch. Biochem. Biophys. 
273: 466-478. 
31.	  Carbonera, D. and Azzone, G.F. (1988) Biochimica et Biophysica 
Acta. 943: 245-255. 
32.	  Novgorodov, S.A., Gudz, T.I., Kushnareva, Y.E., Zorov, D.B. and 
Kudrjashov, Y.B. (1990) FEBS. 270: 108-110. 
33.	  Petronilli, V., Cola, C., and Bernardi, P. (1993) J. Biol. Chem. 268: 
1011-1016. 
34.	  Bernardi, P. (1992) J. Biol. Chem. 267: 8834-8839. 
35.	  Beatric, M.C., Stiers, D.L., and Pfeiffer, D.R. (1982) J. Biol. Chem. 
257: 7161-7171. 
36.	  Rizzoto,R., Pitton, G., and Azzone, G.F. (1987) Eur. J. Biochem. 
162: 239-249. 
37.	  Nicholls, D.G. and Brand, M.D. (1980) Biochem. J.  188: 113-118. 
38.	  Schlogel, J., Schweizer, M., and Richter, C. (1992) Biochem. J. 
285: 65-69. 100 
V. OXIDATION OF PYRIDINE NUCLEOTIDES AND DEPLETION OF 
ATP AND ADP DURING CALCIUM- AND INORGANIC PHOSPHATE­
INDUCED MITOCHONDRIAL PERMEABILITY TRANSITION 
Abstract 
We have examined the pyridine and adenine nucleotide status during 
calcium- and inorganic phosphate-induced permeability transition. 
Calcium- and inorganic phosphate-induced permeability transition is 
accompanied by the rapid oxidation of pyridine nucleotides and depletion 
of ATP and ADP with conversion to AMP. The addition of cyclosporin A, 
a potent inhibitor of the permeability transition, prevented the oxidation 
of pyridine nucleotides and depletion of ATP and ADP. 1 0 1
 
Introduction 
The inner membrane of isolated mitochondria becomes permeable 
when treated with Ca2+ and inorganic phosphate (Pi) due to the activation 
of a Ca2+-dependent inner membrane pore. Activation or opening of this 
pore, referred to as permeability transition, results in the nonselective 
release of small matrix solutes, such as GSH and Ca2+, loss of coupled 
functions, and large amplitude swelling (1-6).  The immunosuppressive 
cyclic peptide, cyclosporin A (CsA) is a potent inhibitor of permeability 
transition and its consequences (2-4). 
Many different compounds in the presence of Ca2+ induce 
permeability transition in isolated mitochondria by mechanisms which 
are thought to be numerous (7). Several studies have suggested  that 
inducing agents such as t-butylhydroperoxide, hydrogen peroxide, 
acetoacetate, or oxalacetate induces permeability transition by the 
oxidation of pyridine nucleotides (7-10). Other agents, such as 
pyrophosphate and phosphoenol pyruvate, deplete adenine nucleotides 
and induce permeability transition (7).  Pi is an example of an inducing 
agent that previously was thought not to change the redox status of the 
pyridine nucleotides or deplete ATP or ADP pools (10-14). 
In this chapter, we have examined the status of NADH, NADPH, 
ATP, ADP, and AMP during Ca2 + and Pi-induced permeability transition. 
Our findings indicate that Ca2+- and Pi-induced permeability transition 
results in the rapid oxidation of NADH and NADPH and the depletion of 
ATP. Treatment with CsA prevented these changes in mitochondrial 
energy status. 102 
Experimental Procedures 
Materials 
All chemicals were purchased from commercial sources and were 
of the highest quality available. CsA was a generous gift from Dr. Sue 
Kohlhepp (Providence Hospital, Portland, OR). CsA was dissolved in 
100% ethanol (0.5 mM stock) and stored at 4°C. 
Mitochondrial Preparation 
Mitochondria were isolated from the livers of male Sprague-
Dawley rats (325-375 g) according to the method of Schnaitman and 
Greenwalt (15). Differential centrifugation was used with isolation buffer 
containing 220 mM mannitol, 70 mM sucrose, 2 mM HEPES, 0.5 mM 
EGTA, and 0.5 mg/in' bovine serum albumin, pH 7.4.  Mitochondria were 
washed twice in isolation buffer devoid of EGTA, pH 7.0. After the final 
wash, mitochondria were suspended in 5-7 ml of incubation buffer 
containing 213 mM mannitol, 71 mM sucrose, 10 mM succinate and 3 mM 
HEPES, pH 7.0. Protein concentration was determined by the method of 
Bradford (15) with bovine serum albumin as the standard. 
Mitochondria' Incubations 
Mitochondria (1 mg protein/m1) were suspended in 10 ml 
Erlenmeyer flasks containing incubation buffer alone (untreated control) 
or 70 i.rM Ca2+ and 3 mM Pi or 70 gM Ca2+ and 3 mM Pi plus 0.5 piM CsA. 
Aliquants for initial time points were taken immediately following the 103 
addition of mitochondria and prepared for analysis of pyridine and 
adenine nucleotides. 
Biochemical Analysis 
Pyridine and adenine nucleotides were measured by high-
performance liquid chromatography (HPLC) according to the method of 
Jones (17). Briefly, 1 ml samples were transferred to microcentrifuge tubes 
containing either 0.5 ml 10% perchloric acid (PCA) for the extraction of 
NAD+, NADP+, ATP, ADP, and AMP or 0.1 ml 0.5 M KOH in 50% ethanol 
and 0.35% cesium chloride for the extraction of NADH and NADPH. 
Following extraction for 15 min on ice, samples were immediately frozen 
at -80°C. until analysis, which was conducted within 24 hrs of sample 
preparation. Just prior to analysis, samples were thawed and acid extracts 
neutralized with an equal volume of both 10 M KOH and 1 M K2PO4; 
samples were then centrifuged at 13,000 g for 30 s to remove debris and 
assayed for either reduced pyridine nucleotide (base extraction) or oxidized 
pyridine nucleotides and adenine nucleotides (acid extraction). 104 
Results 
Treatment of mitochondria with 70 JAM Ca2+ and 3 mM Pi (CaPi) 
resulted in the rapid and extensive oxidation of NADH as shown in 
Figure V. 1. NADH decreased 61% and 89% within a 5- and 10- min 
incubation period, respectively (Figure V. 1A). The loss of NADH can be 
accounted for in the recovery of NAD+ (Figure V. 1B). Similarly, NADPH 
underwent oxidation to NADP+ (Figure V. 2A,B), although there was a 
slight delay in oxidation as compared to NADH (Figure V. 1A,B). 
Treatment with 0.5 1AM CsA prevented oxidation of both NADH and 
NADPH as induced by CaPi treatment (Figure V.s 1 & 2). 
The impact of CaPi on the adenine nucleotide status was also 
determined under these conditions as shown in Figure V. 3. By 5 min, 
ATP was depleted by nearly 70% and was accounted for by a transient rise 
in ADP (Figure V. 3B), and in the eventual formation of AMP (Figure V. 
3C). Addition of 0.5 1..tM CsA to incubation buffer containing CaPi 
prevented ATP depletion. Addition of CsA resulted in a slight increase in 
the ATP concentration (Figure V. 3A) while ADP and AMP levels were 
somewhat lower than untreated control samples (Figure V. 3B,C). 105 
Discussion 
This report demonstrates that CaPi-induced permeability transition 
involves the oxidation of NADH and NADPH and the depletion of ATP 
and ADP. The addition of CsA, a potent inhibitor of permeability 
transition, prevented these changes in mitochondrial energy status. The 
effect of CaPi-induced inner membrane permeability has not previously 
been reported to involve redox changes in pyridine nucleotides or deplete 
ATP to our knowledge. 
We have previously reported that mitochondrial GSH is rapidly 
released through the inner membrane pore during CaPi-induced 
permeability transition (3). The release of GSH occurs without formation 
of GSSG. It is possible that the GSH redox cycle is so efficient that detection 
of GSSG is not possible under these conditions, possibly explaining the 
oxidation of pyridine nucleotides. Under these conditions, there was also 
no detection of lipid peroxidation as determined by the thiobarbituric acid 
(TBA) assay (data not shown). 
Carbonera et al. (14) reported that the addition of the antioxidant, t­
butylhydroxytoluene (BHT) to Ca2+- and Pi-treated mitochondria 
prevented permeability transition. They proposed that Pi may contribute 
to inner membrane permeability by increasing the formation of oxygen 
radicals due to enhancement of the electron leak. They reported no 
change in the mitochondrial GSH redox status. Novgorodov et al. (18) 
reported that BHT, in the presence of Ca2+ and Pi, prevented the collapse 
of the membrane potential and Ca2+ release. Although evidence of lipid 
peroxidation as measured by the TBA assay was not observed, they 106 
proposed that initial steps in lipid peroxidation control Ca2+- and Pi-
induced permeability transition. 
There is growing interest on the similarities between ischemic 
reperfusion injury, chemical toxicity, and mitochondrial permeability 
transition; a central component being the oxidation of pyridine 
nucleotides. Early studies by Lehninger (19) showed a strong relationship 
between the ability of mitochondria to retain Ca2+ in the presence of a 
high ratio of reduced:oxidized pyridine nucleotides. A recent study by 
Takeyama et al. (20) showed that 02 metabolites derived from the 
xanthine-xanthine oxidase system triggered a CsA-sensitive and Ca2+ ­
dependent membrane transition that depleted pyridine nucleotides. 
Permeability transition induced with oxidants that are substrates for 
glutathione peroxidase, including t-butylhydroperoxide or hydrogen 
peroxide, is thought to be mediated by oxidation of pyridine nucleotides 
that are formed during the reduction of GSSG (21). 
We observed that CaPi-induced permeability transition rapidly 
depleted ATP. Within 5 min, the ATP concentration was depleted nearly 
70%, while ADP and AMP levels increase nearly 100%.  The increase in 
ADP was transient, and after 5 min, the level decreases to below untreated 
control values while AMP levels increased, accounting for the loss of ATP 
and ADP. 
Several studies indicate the importance of metabolic energy, 
particularly ATP and ADP, in maintaining cell viability under various 
conditions that are also prevented by CsA (4, 22, 23). Halestrap and 
Davidson (23) proposed that the permeability transition pore is the 
adenine nucleotide translocase that has changed conformation.  Both ATP 107 
and ADP are positive effectors against pore formation by stabilizing the 
nonpermeable state or "m" conformation. Agents inducing the "c" 
conformation of the carrier promotes inner membrane permeability. 
Le-Quoc and Le-Quoc (24) report that oxidation of pyridine nucleotides is 
correlated with the stabilization of the "c" conformation of the adenine 
nucleotide carrier and therefore promote inner membrane permeability. 
In summary, we report that Ca Pi induced permeability transition 
was accompanied by the rapid oxidation of NADH and NADPH and the 
depletion of ATP. The oxidation of pyridine nucleotides may be related to 
early stages of inner membrane alterations associated with CaPi-induced 
permeability transition. The ability of CsA to maintain energy status 
during permeability transition may be important in understanding the 
mechanism(s) by which it prevents this mitochondrial injury as induced 
by inorganic phosphate. 108 
Figure V. 1.  Total mitochondrial NADH and NAD+. Mitochondria 
(1 mg/ml) were incubated in the absence (control) or presence of either 70 
i.tM Ca2+ and 3 mM Pi (Ca Pi) or Ca Pi plus 0.5 µM CsA (CaPiCsA). 
Samples (1 ml) were taken at the times indicated and prepared for the 
analysis of (A) NADH and (B) NAD+ as described in Experimental 
Procedures. n = 3-4 ± SEM. 109 
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Figure V. 1. 1 1 0 
Figure V. 2. Total mitochondrial NADPH and NADP+.  Mitochondria 
(1 mg/ml) were incubated in the absence (control) or presence of either 
70 IIM Ca2+ and 3 mM Pi (Ca Pi) or Ca Pi plus 0.5 p,M CsA (CaPiCsA). 
Samples (1 ml) were taken at the times indicated and prepared for the 
analysis of (A) NADPH and (B) NADP+  as described in Experimental 
Procedures. n = 3-4 ± SEM. 1 1 1
A 
0-- Control 
----- Ca Pi 
--ir-- CaPiCsA 
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minutes 
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0  5  10  15 20 
minutes 
Figure V. 2. 1 1 2 
Figure V. 3. Total mitochondrial ATP, ADP, and AMP.  Mitochondria (1
mg/ml) were incubated in the absence (control) or presence of either 70 
1.tM Ca2+ and 3 mM Pi (Ca Pi) or Ca Pi plus 0.5 11M CsA (CaPiCsA).
Samples (1 ml) were taken at the times indicated and prepared for the
analysis of (A) ATP, (B) ADP, and (C) AMP as described in Experimental 
Procedures. n = 3-4 ± SEM. 1 1 3
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VI. RELEASE OF NAD± and NADP± DURING CALCIUM- AND 
PHOSPHATE-INDUCED PERMEABILITY TRANSITION OCCURS BOTH 
WITH AND WITHOUT LARGE AMPLITUDE SWELLING 
Abstract 
The mitochondrial inner membrane is normally impermeable  to most 
substances, with the entrance and exit of molecules being a highly 
regulated process. However, the inner membrane of isolated 
mitochondria undergo acute (<5 min) alterations in the presence of Ca2+ 
and near physiological levels of Pi. The Ca2+-dependent inner 
membrane alterations, referred to as permeability transition, are inhibited 
by cyclosporin A and characterized by inner membrane permeability to 
small (<1200 Da) solutes, uncoupling of the mitochondria, and large 
amplitude swelling. We recently reported that during permeability 
transition induced by calcium and Pi, NADH and NADPH are rapidly 
oxidized and that ATP, and ADP are rapidly depleted. Recently, we 
observed that the addition of either antimycin, oligomycin, or sulfide to 
Ca2+ and Pi treated mitochondria prevented large amplitude swelling of 
the mitochondria, but did not prevent cyclosporin A-sensitive inner 
membrane permeability. The purpose of our current study is to 1) 
determine if NAD(H) or NADP(H) (700-835 Da) are released during Ca2+ 
and Pi-induced permeability transition since these molecules are 
relatively small and 2) determine the effects of antimycin, oligomycin, 
and sulfide on pyridine, as well as adenine nucleotide status in 
mitochondria treated with Ca2+ and Pi. Our findings indicate that during 1 1 8
 
Ca2+- and Pi- induced permeability transition,  NADH and NADPH 
oxidation occurs intramitochondrially, followed by the release of NAD+ 
and NADP+, presumably via the inner membrane pore. We also report 
that the addition of antimycin, oligomycin, or sulfide to Ca2+ and Pi 
treated mitochondria results in varying degrees of NADH and NADPH 
oxidation and release of NAD+ and NADP+ in the absence of large 
amplitude swelling. Our findings suggest that maintenance of 
endogenous adenine nucleotides, especially ADP, may be important in 
modulating permeability transition. 1 1 9
 
Introduction
 
The inner membrane of mitochondria isolated from a variety of 
tissues become permeable following activation or deregulation of a Ca2+ ­
dependent inner membrane pore (1-4). This process, referred to as 
permeability transition requires the presence of  a second agent, termed an 
inducing agent (1,4).  Many different inducing agents have been identified; 
examples include near physiological levels of inorganic phosphate (Pi), t­
butylhydroperoxide, and sulfhydryl reagents (4).  The mechanism(s) by 
which the various agents induce permeability transition is not completely 
understood; however, it is postulated that they may all act on a similar 
protein structure (1,4). 
Opening or activation of this inner membrane pore with Ca2+ and 
Pi results in the release of small (<1200 Da) matrix solutes such as GSH 
(307 Da) and Ca2+, large amplitude swelling, and a loss of coupled 
functions. (4, 9-11). Cyclosporin A (CsA), an immunosuppressive cyclic 
peptide, is a potent inhibitor of the permeability transition (5-6).  The 
mechanism of CsA's inhibition is thought to involve the binding of CsA 
to the matrix protein, cyclophillin (7-8, 12). 
Although the physiological relevance of such a pore remains 
uncertain, there is increasing evidence suggesting that the opening and 
closing of this inner membrane pore is a highly regulated process with 
several different control sites. This may explain why many structurally 
and functionally different inducing agents, including Pi, sulfhydryl 
reagents, oxidants, and heavy metals, induce the Ca2+-dependent 
permeability transition (4). 120 
Inducing agents such as t-butyl hydroperoxide and hydrogen 
peroxide are thought to mediate permeability transition due to the 
oxidation of NADH and NADPH (4, 13-14). The inducing agent pi was 
not previously thought to alter pyridine nucleotide ratios and is therefore 
often studied in comparison to agents, such as t-butylhydroperoxide 
which induce changes in pyridine nucleotide ratios (15-17). 
We have recently reported that during Ca2+ and Pi induced 
permeability transition both NADH and NADPH are extensively oxidized 
and ATP and ADP are depleted within several minutes (22). This is a 
novel finding since Pi induced permeability transition was not previously 
thought to alter pyridine nucleotide ratios or adenine nucleotide status. 
We have also observed conditions in which inner membrane 
permeability occurs without large amplitude swelling (27).  These 
conditions were observed when mitochondria were treated with either 
antimycin, oligomycin, or sulfide in combination with Ca2+ and Pi (27). 
The purpose of the current study is to 1) determine if NAD(H) or 
NADP(H) (700-835 Da) release occurs during Ca2+- and Pi-induced 
permeability transition since these molecules are normally impermeable 
to the inner membrane and relatively small (<1200 Da) and 2) determine 
the status of both pyridine, and adenine nucleotides following treatment 
with either antimycin, oligomycin, or sulfide during Ca2+- and Pi-
induced permeability transition. 1 2 1
 
Experimental Procedures 
Mitochondrial Preparation 
Isolated mitochondria were prepared by differential centrifugation 
according to the method of Schnaitman and Greenwalt (18).  Briefly, livers 
of male Sprague-Dawley rats (325-375 g) (Simonsen Labs, Gilroy, CA) were 
excised and homogenized in isolation buffer containing 220 mM 
mannitol, 70 mM sucrose, 2 mM HEPES, 0.5 mM EGTA, and 0.5 mg/ml 
bovine serum albumin, pH 7.4. Mitochondria were washed twice in 
isolation buffer devoid of EGTA, pH 7.0. 
After the final wash, the mitochondrial pellets were suspended (25­
30 mg/ml) in incubation buffer containing 213 mM mannitol, 71 mM 
sucrose, 10 mM succinate, and 3 mM HEPES, pH 7.0. Mitochondrial protein 
was determined spectrophotometrically by the method of Bradford (19) 
with bovine serum albumin as the standard. 
Mitochondrial Incubations 
Mitochondria were added to 10-m1 Erlenmeyer flasks (1 mg 
protein/nil) containing incubation buffer plus the various treatments 
described in the figure legends. After briefly swirling the flask, 1.0 ml 
samples were taken immediately following the addition of mitochondria. 
These samples constitute the initial time points.  Mitochondrial 
suspensions were exposed to atmospheric air throughout the remainder 
of the incubation period. Aliquants (1m1) of mitochondrial suspensions, 
taken at the times indicated in the figure legends and prepared for 
analysis of pyridine and adenine nucleotides as described below. 122 
Biochemical Analysis 
Intra- and extra-mitochondrial pyridine and adenine nucleotides 
were measured according to the HPLC method of Jones (20) with the 
following modifications to accommodate mitochondrial samples.  Briefly, 
1 ml samples containing 1 mg protein were removed from incubation 
flask at the appropriate time point, transferred to microcentrifuge tubes 
and centrifuged at 13,000 g for 30 s to separate the suspended 
mitochondria from the incubation buffer. A sample (0.500 ml) of the 
supernatant (extra-mitochondrial) was transferred to microcentrifuge 
tubes containing either 0.100 ml 10% perchloric acid (PCA) for the analysis 
of ATP, ADP, AMP, NADP+, and NAD+ or 0.100 ml 0.5 M KOH in 50% 
ethanol and 0.35% cesium chloride for the analysis of NADH and 
NADPH, and then frozen immediately at -80° C. The remaining 
supernatant was carefully discarded by aspiration. The mitochondrial 
pellets were suspended in either 0.500 ml 10% PCA for extraction of 
intramitochondrial ATP, ADP, AMP, NADP+, and NAD+ or 0.100 ml 0.5 
M KOH in 50% ethanol and 0.35% cesium chloride for extraction of 
NADPH and NADH. The samples were immediately iced for 15 min, 
sonicated for 5 s, and then frozen at -80° C. Prior to analysis, samples were 
thawed, the acid extracted samples neutralized with 10 mM KOH and 1 M 
KH2PO4, centrifuged at 13,000 g for 30 s to remove insoluble debris, and 
assayed for either NADH and NADPH (base extraction) or NAD+, 
NADP+, ATP, ADP, and AMP (acid extraction). All samples were assayed 
within 24 hr of collection. 123 
The spectrophotometric determinations of pyridine nucleotides 
were monitored at 340 nm and 370 nm in an Aminco DW2000 
spectrophotometer operated, in dual beam mode. 124 
Results 
Ca2+ and Pi-induced permeability transition is accompanied by the 
rapid and extensive oxidation of NADH and NADPH (22). Since pyridine 
nucleotides are relatively small molecules (<850 Da) and normally 
impermeable to the inner membrane, we hypothesize that release of 
pyridine nucleotides could occur through the putative inner membrane 
pore. To test this hypothesis, both intra- and extra-mitochondrial 
NAD(H) and NADP(H) levels were measured during permeability 
transition induced with 70uM Ca2+ and 3 mM Pi (CaPi). 
As shown in Figures VI. 1A and 2A, mitochondrial NADH and 
NADPH pools are decreased roughly 50% within 5-min following 
treatment with CaPi. This decrease is not accounted for by an increase in 
extramitochondrial NADH and NADPH (Figures VI. 1A and 2A). The 
depletion of NADH and NADPH are accounted for as NAD+ and NADP+ 
which are found both intra- and extra-mitochondrially (Figures VI. 1BC 
and 2BC). The addition of 0.5 µM CsA, a potent inhibitor of permeability 
transition, prevented the oxidation and release of NAD+ and NADP+ 
(Figures VI. 1ABC and 2ABC). 
To discount the possibility that NADH and NADPH are released 
from the matrix, and then subsequently oxidized extramitochondrially, 
we monitored spectrophotometrically the redox state of exogenous 
NADH and NADPH during CaPi induced permeability transition. The 
addition of CaPi to mitochondrial suspensions resulted in the oxidation 
of endogenous pyridine nucleotides as demonstrated in Figure VI. 3 by 
the decrease in absorbance and 340 and 370nm. Following oxidation of 125 
endogenous NADH and NADPH, the subsequent addition of exogenous 
NADH and NADPH increased the absorbance, which was maintained 
throughout the incubation period, indicating that no further oxidation 
was occurring. 
We have previously observed that the addition of either 
oligomycin (3 11M), sulfide (0.5 mM) or antimycin (111.M)  to incubation 
buffer containing CaPi prevented mitochondrial large amplitude swelling 
but did not prevent inner membrane permeability (27). Inner membrane 
permeability was indicated by the CsA-sensitive release of matrix GSH 
and Ca2+. This suggested that activation of the putative Ca2+-dependent 
pore could occur without large amplitude swelling.  As part of the 
present study, we therefore determined if mitochondrial energy status in 
the form of NADH, NADPH, ATP and/or ADP was preserved in the 
presence of the metabolic inhibitors. As shown in Figures VI. 4A and 5A, 
the addition of oligomycin (3 0.4), sulfide (0.5 mM) or antimycin (111.M) to 
incubation buffer containing CaPi decreased NADH and NADPH to 
varying degrees. 
Treatment with oligomycin and sulfide maintained NADH levels 
40% and 20%, respectively, greater than CaPi treatment alone, whereas the 
addition of antimycin potentiated the loss of NADH by 20% (Figure VI. 
4A). The observed loss of NADH and NADPH was not accounted for by 
the recovery of NADH and NADPH extramitochondrially (Figures VI. 4A 
and 5A). With all treatments, the NADH lost was recovered as NAD+ 
and detected both intra- and extra-mitochondrially (Figures VI. 4ABC). 
Interestingly, the amount detected extramitochondrially does not 
correspond to the amount of NADH lost. For example, treatment with 126 
antimycin resulted in increased formation of NAD+ compared to Ca Pi 
treatment alone (Figures VI. 4 BC), although antimycin treated 
mitochondria released less NAD+ (Figure VI. 4C). 
The mitochondrial NADPH pool followed the same pattern of 
oxidation and release as observed with NADH following treatment with 
the metabolic inhibitors. The loss of NADPH was accounted for as 
NADP+, which was recovered both intra- and extra-mitochondrially 
(Figures VI. 5A,B,C).  The release of NADP+ from the matrix followed 
the same pattern as that observed with NAD+ following a 5-min 
incubation (Figure VI. 4C). The observed pattern is that treatment with 
Ca Pi resulted in the greatest release of NAD+ and NADP+, followed by 
treatment with antimycin + Ca Pi, oligomycin + Ca Pi, and then sulfide + 
Ca Pi. 
Table 1 lists the pyridine nucleotide redox couples of NADH:NAD+ 
and NADPH:NADP+ following a 5-min incubation. Treatment with Ca Pi 
results in greatly diminished ratios of both NADH:NAD+ and 
NADPH:NADP+, as compared to untreated controls and CsA treated 
mitochondrial samples.  However, the addition of antimycin to Ca Pi 
treated mitochondria resulted in the redox ratios of both NADH:NAD+ 
and NADPH:NADP+ less than that observed with Ca Pi treatment alone. 
The addition of oligomycin or sulfide to Ca Pi treated mitochondria 
preserved the NADH:NAD+ and NADPH:NADP+ redox couples 
compared to Ca Pi treatment alone. 
Measurements of ATP, ADP, and AMP with the various treatments 
are reported in Table 2. Treatment with Ca Pi resulted in the depletion of 
ATP and ADP by 5 min, with 75% of the adenine pool recovered as AMP 127 
(Table 2). Addition of 0.5 [iM CsA eliminated this effect, resulting in 
increased levels of ATP, slightly increased levels of ADP, and decreased 
AMP levels compared to untreated control samples (Table 2). 
The presence of the metabolic inhibitors in addition to CaPi 
preserved ATP and/or ADP levels compared to CaPi treatment alone 
(Table 2). The addition of 3 p.M oligomycin to CaPi treated mitochondria 
maintained ATP levels similar to control values at 5 min, while ADP loss 
was minimal as compared to CaPi treatment alone. The addition of 
sulfide (0.5 mM) or antimycin (1 ilM), in conjunction with CaPi, did not 
sustain ATP levels any differently than CaPi treatment alone;  however, 
ADP levels were preserved as compared to CaPi treatment alone (Table 2). 
The energy charge [(ATP + 0.5ADP)/(ATP + ADP + AMP)], which 
designates energy status, indicates that the presence of antimycin, sulfide, 
or oligomycin preserved energy status to varying degrees compared to 
CaPi treatment alone. Following treatment with CaPi, the energy charge 
dropped to 0.158 as compared to untreated controls (0.351).  Treatment of 
mitochondria with either oligomycin, sulfide, or antimycin plus CaPi 
resulted in energy charge values of 0.409, 0.209, and 0.169 respectively, 
following a 5-min incubation. 
Treatment with the respiratory inhibitors maintained ADP levels 
at least 40% greater than observed with CaPi treatment alone.  Since the 
addition of metabolic inhibitors prevented large amplitude swelling but 
not inner membrane permeability (27), we tested whether ADP could 
prevent large amplitude swelling during CaPi treatment. Mitochondria 
were incubated with increasing concentrations of exogenous ADP in the 
presence of CaPi (Figure VI. 6). Mitochondria undergo large amplitude 128 
swelling in the presence of Ca Pi (Figure VI. 6A). The addition ADP in the 
presence of Ca Pi inhibited large amplitude swelling in a dose dependent 
manner (Figure VI. 6B-D). At the highest dose of ADP (150 MM), large 
amplitude swelling was abolished during Ca Pi induced permeability 
transition (Figure VI. 6D). 129 
Discussion 
The major findings we report demonstrate that CaPi induced 
permeability transition is accompanied by intramitochondrial oxidation 
of the pyridine nucleotide pool, with the selective efflux of the NAD+ and 
NADP+. This contradicts the idea that CaPi induced permeability 
transition did not involve alterations in the pyridine or adenine 
nucleotide status. Although the mechanism by which CaPi treatment 
results in the oxidation of NADH and NADPH is not clear, apparently it 
does not involve the oxidation of GSH or lipid peroxidation, as no 
evidence of either has been detected in this system (11). In fact, under 
these conditions, GSH is rapidly and nearly completely released as GSH 
(reduced) from the matrix with a 5-min incubation (11). 
Since pyridine nucleotides are of low molecular weight (<1200 Da), 
they presumably could be released nonspecifically through the Ca2+­
dependent, CsA-sensitive pore of the permeability transition (5). 
However, extramitochondrial NADH and NADPH levels detected during 
permeability transition were similar to untreated control levels.  This 
suggests that either NADH and NADPH are not released from the 
mitochondrial matrix during permeability transition, or they are released 
and rapidly oxidized extramitochondrially. To test the latter, exogenous 
NADH and NADPH were added to mitochondrial suspensions following 
treatment with CaPi. These suspensions were monitored 
spectrophotometrically for redox changes in NADH and NADPH.  The 
addition of CaPi to mitochondrial suspensions resulted in the expected 
oxidation of NADH and NADPH. Subsequent addition of exogenous 130 
NADH and NADPH did not result in any further oxidation. This 
provides additional evidence that NADH and NADPH do not traverse 
the inner membrane pore. 
It is unknown as to why NAD(P)+, but not NAD(P)H, are 
apparently able to efflux through the inner membrane pore during CaPi 
induced permeability transition. One possible explanation is that NADH 
and NADPH are protein bound and therefore unavailable to traverse the 
inner membrane pore; NAD+ and NADP+ are perhaps unbound and 
free to efflux through the permeability transition pore. Another possible 
explanation centers on the issue of pore selectivity, with the pore 
selectively releasing NAD+ and NADP+. Although the Ca2+-dependent 
pore has generally been regarded as being nonselective to small (<1200 Da) 
matrix solutes (1), other studies have suggested that inner membrane 
permeability may be more selective than previously thought (21). 
We also measured the status of pyridine and adenine nucleotide in 
mitochondria treated with either oligomycin, sulfide, or antimycin in the 
presence of CaPi. The addition of oligomycin, sulfide, or antimycin to 
CaPi treated mitochondria prevented mitochondrial large amplitude 
swelling but not the CsA-sensitive release of GSH and Ca2+ (22). 
Treatment of mitochondria with oligomycin or sulfide in the presence of 
CaPi preserved the pyridine nucleotide redox couple ratios compared to 
CaPi alone, but less than untreated control samples.  On the other hand, 
antimycin, in the presence of CaPi, potentiated the decrease in pyridine 
nucleotide redox couple ratios. 
The increased oxidation of NADH and NADPH observed with 
antimycin treatment may be due to an increase in H202. Inhibition of 1 3 1 
electron transport with antimycin is thought to result in an increase in 
H202 formation due to the electron leakage at ubiquinone (23-24). 
However, formation of GSSG was not detected and GSH was released to 
the extramitochondrial environment within 5 min. It may be possible 
however, that the efficiency of the GSH redox cycle is such that detection 
of GSSG is not possible under these circumstances;  GSSG reductase 
activity may be reflected in the observed increase in NADP+. 
Inducing agents such as t-butyl hydroperoxide or hydrogen 
peroxide are thought to induce permeability transition due to the 
oxidation of pyridine nucleotides (4, 13-14). However, based on the 
findings we report, the redox status of pyridine nucleotides alone does not 
seem to regulate permeability transition.  This observation is based on the 
finding that treatment with antimycin resulted in an increased oxidation 
of both NADH and NADPH compared to Ca Pi treatment alone;  but 
unlike Ca Pi treatment, the addition of antimycin abolished large 
amplitude swelling and solute release was diminished. Although these 
findings do not dispute the significance of the pyridine nucleotide redox 
status in regulating permeability transition, they do seem to suggest that 
pyridine nucleotide redox status alone does not determine permeability 
transition status. 
An interesting effect of the metabolic inhibitors in the presence of 
Ca Pi was the preservation of ADP. Oligomycin, sulfide, and antimycin 
treatment in the presence of Ca Pi treated mitochondria maintained ADP 
levels 57%, 46%, and 40%, respectively, greater than Ca Pi treatment alone 
following a 5-min incubation. Previous studies have reported that ADP 
can prevent permeability transition  (7,25-26). Although the metabolic 132 
inhibitors preserved ADP levels and prevented large amplitude swelling, 
inner membrane permeability was not inhibited (27). These findings 
suggest that permeability transition occurs to varying degrees in 
mitochondria, both with and without swelling, and varied degrees of 
solute release. The metabolic state of the mitochondria, as reflected by 
levels of ADP, ATP, pyridine nucleotides, membrane potential, and/or 
other parameters may determine the degree of permeability transition. 
To determine if ADP could prevent large amplitude swelling of the 
mitochondria in the presence of Ca Pi, we monitored large amplitude 
swelling in the presence of increasing concentrations of ADP. Our 
findings suggest that ADP prevented large amplitude swelling in a 
concentration-dependent manner in the presence of Ca Pi. Since addition 
of the metabolic inhibitors prevented large amplitude swelling and 
preserved ADP levels compared to Ca Pi treatment alone, this may 
partially explain how the metabolic inhibitors prevented large amplitude 
swelling. 
In conclusion, we report that during Ca Pi induced permeability 
transition, NADH, NADPH, ATP and ADP are rapidly depleted. Under 
these conditions, NADH and NADPH undergo extensive oxidation with 
the subsequent release of NAD+ and NADP+ from the mitochondrial 
matrix within a 5-min incubation. This release occurs through the 
putative Ca2+-dependent inner membrane pore as CsA prevented the 
oxidation and release of pyridine nucleotides. ATP and ADP are also 
rapidly depleted with the concomitant formation of AMP during Ca Pi 
treatment. The addition of either oligomycin, sulfide, or antimycin 
preserved NADH, NADPH, ATP, and ADP to varying degrees. 133 
Maintenance of ADP by the respiratory inhibitors may contribute to the 
partial protection observed against permeability transition. 134
 
Table VI. 1. NADH:NAD+ and NADPH:NADP+ Redox Ratios. 
NADH:NAD+ and NADPH:NADP+ ratios were determined following a 5­
min incubation in the absence (control) or presence of either 70 .tM Ca2+ 
and 3 mM Pi (CaPi) or CaPi plus 0.511M CsA (+CsA), CaPi plus 3 p.M 
oligomycin ( +Oligomycin), CaPi plus 0.5 mM sulfide (+Sulfide), or CaPi 
plus li.tM antimycin (+Antimycin). 
NADH ;NAD±  NADPH: NADP± 
Control  4.97  13.50 
CaPi  1.00  0.96 
+CyA  5.81  7.88 
+Oligomycin  2.56  3.25 
+Sulfide  1.58  1.43 
+Antimycin  .079  0.49 TABLE VI.2. Mitochondria (1mg/mL) were incubated in the presence of 70 mM Ca2+ and 3 mM Pi
(Ca Pi) alone or with the addition of either 0.5 mM cyclosporin A, 3 mM oligomycin, 0.5 mM
sulfide, or 1 mM antimycin. Samples were taken at the times indicated and analyzed by HPLC for
ATP, ADP, and AMP as described in Experimental Procedures. 
n=3-5 (-± SE)
 
ADENINE NUCLEOTIDES EXPRESSED nmols/mg
 
ATP  ADP  AMP  TOTAL 
*I  **E  I E  I E 
Control 
0 min  2.2 (.34)  1.7 (.18)  5.5 (.55)  .42 (.04)  7.6 (.84)  .39 (.12)  17.8 
5 min  1.8 (.38)  1.5 (.16)  5.0 (.80)  .32 (.03)  8.2  (.61)  .17  (.10)  17.0 
Ca Pi 
3 min  1.2 (.12)  2.0 (.59)  2.7 (.28)  1.4 (.20)  7.8  (1.4)  2.8  (.72)  17.9 
5 min  0.9 (.09)  0.3  (.04)  1.8 (.18)  1.1  (.11)  6.6  (1.1)  6.0 (.33)  16.8 
" + CsA 
3 min  2.9 (.28)  1.9  (.53)  7.6 (.51)  0.1  (.09)  4.4  (1.1)  0.03  17.0 
5 min  2.7 (.13)  2.9 (.72)  7.1  (.53)  0.4  (.04)  6.3  (.82)  0.1 (.05)  19.5 
" + Oligomycin 
3 min  2.3 (.20)  1.8 (.14)  4.2 (.18)  0.9  (.56)  5.2  (.85)  0.5  (.42)  15.0 
5 min  2.4  (.32)  1.3  (.31)  4.2  (.80)  1.4 (.29)  5.0 (.80)  1.6 (1.1)  15.9 
" + Sulfide 
3 min  1.1  (.24)  0.5  (.17)  3.6 (.44)  0.5 (.02)  6.9  (.77)  3.3  (.48)  15.9 
5 min  1.0 (.22)  0.3  (.01)  3.3 (.43)  0.5 (.08)  6.0  (1.3)  4.2 (.44)  15.3 
" + Antimycin 
3 min  1.0 (.22)  0.0  3.3 (.62)  0.3  (.11)  6.6 (1.3)  4.4 (.47)  15.6 
5 min  1.0 (.19)  0.0  3.0 (.60)  0.4  (.03)  5.6 (.63)  5.9 (.66)  16.0
*I = Intramitochondrial  ** E = Extramitochondrial 136 
Figure VI. 1. Intra- and extra-mitochondrial NADH and NAD+.
 
Mitochondria (1mg/m1) were incubated in the absence (control) or
 
presence of 7011M Ca2+ and 3 mM Pi (Ca Pi) or Ca Pi plus 0.5 p.M
 
cyclosporin A (CaPiCsA). Aliquots (1m1) were taken at the times
 
indicated and analyzed for (A) intra- and extramitochondrial NADH, (B)
 
intramitochondrial NAD± or (C) extramitochondrial NAD+ as
 
described in Experimental Procedures.
 
n=3-4 ± S.E.M.
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Figure VI. 2.  Intra- and extra-mitochondrial NADPH and NADP+. 
Mitochondria (1mg/m1) were incubated in the absence (control) or 
presence of 7011M Ca2+ and 3 mM Pi (Ca Pi) or Ca Pi plus 0.5 gM 
cyclosporin A (CaPiCsA). Aliquots (1m1) were taken at the times 
indicated and analyzed for (A) intra- and extramitochondrial NADPH, 
(B) intramitochondrial NADP+ or (C) extramitochondrial NADP+ as 
described in Experimental Procedures. 
n=3-4 ± S.E.M. 139 
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Figure VI. 3.  Spectrophotometric determination of the redox state of 
exogenous NADPH and NADH. Pyridine nucleotide oxidation occurred 
in mitochondrial suspensions (1 mg/ml) treated with (1) 70 04 Ca2+ 
and 3 m1V1Pi. Exogenous NADH (2) and NADPH (3) were added 
following the oxidation of endogenous pyrdine nucleotides and 
monitored for redox changes. 141 
Figure VI. 4. Effect of metabolic inhibitors on NAD(H). Mitochondria 
(1 mg/mL) were incubated in the presence of 70 1.1M Ca2+ and 3 mM Pi 
(Ca Pi) alone or with the addition of either 31.IM oligomycin, .5 mM 
sulfide, or 11.tM antimycin. Aliquots (1m1) were taken at the times 
indicated and analyzed for (A) intra- and extramitochondrial NADH, (B) 
intramitochondrial NAD+ or (C) extramitochondrial NAD+ as described 
in Experimental Procedures. n=3-4 ± S.E.M. 142 
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Figure VI. 5. Effect of metabolic inhibitors on NADP(H). Mitochondria 
(1 mg/mL) were incubated in the presence of 70 11M Ca2+ and 3 mM Pi 
(Ca Pi) alone or with the addition of either 3 laM oligomycin, .5 mM 
sulfide, or 11.0/1 antimycin. Aliquots (1m1) were taken at the times 
indicated and analyzed for (A) intra- and extramitochondrial NADPH, 
(B) intramitochondrial NADP+ or (C) extramitochondrial NADP+ as 
described in Experimental Procedures. 
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Figure VI. 6. Dose response inhibition of large amplitude swelling by 
exogenous ADP. Mitochondria (1 mg/ml) were treated with: A. 70 1.1M 
Ca and 3 mM Pi (CaPi) ;  B. 60 [tM ADP plus CaPi; C. 80 1.1M ADP plus 
CaPi; and D. 150 [tM ADP plus CaPi and monitored for large amplitude 
swelling. 146 
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VII. SUMMARY, CONCLUSIONS, AND FUTURE STUDIES
 
The studies described in this thesis provide valuable data and 
observations regarding mitochondrial glutathione status, permeability 
transition, and energy status during Ca2+- and inorganic phosphate-
induced permeability transition. 
In particular, this work demonstrates the rapid and nearly complete 
release of mitochondrial glutathione by a Ca2+-dependent mechanism. 
The process is inhibited by CsA which suggests that release of glutathione 
occurs through the putative Ca2±-dependent pore of the permeability 
transition.  The significance of these findings is that glutathione efflux 
from mitochondria may occur under toxicological and pathological 
conditions in which mitochondria are exposed to elevated levels of Ca2+ 
in the presence of near physiological concentrations of inorganic 
phosphate. 
In addition to demonstrating a mechanism of glutathione release 
from mitochondria during permeability transition, the study described in 
Chapter III also demonstrated a mechanism to load mitochondria with 
exogenous glutathione by the controlled opening and closing of the inner 
membrane pore. Exogenous glutathione could be trapped or loaded in 
mitochondria by the controlled opening and closing of the pore with 
Ca Pi, and CsA respectively. Opening and closing of the pore provided a 
mechanism for the uptake of glutathione by mitochondria that was 
greater than glutathione uptake by untreated control mitochondria. This 
observation is significant in that a proposed physiological function of the 
pore is in providing a mechanism for transport of mitochondrial 149 
metabolites. Based upon this finding, cyclical opening and closing of the 
pore physiologically could possibly provide a mechanism to load 
mitochondria with glutathione. 
A significant finding reported in Chapter IV demonstrates that the 
CsA-sensitive permeability transition, accompanied by the release of 
glutathione and Ca2+, can occur without large amplitude swelling. The 
addition of either antimycin, sulfide, or oligomycin to Ca Pi treated 
mitochondria abolished large amplitude swelling, but did not prevent 
inner membrane permeability. Assessment of mitochondrial integrity 
via the light scatter assay or TEM analysis may not accurately reflect the 
biochemical alterations due to changes in mitochondrial inner 
membrane permeability. This is an important observation relevant to 
cellular or isolated mitochondrial studies relying on ultrastructural 
changes as an assessment of mitochondrial integrity. In particular, this 
finding is relevant for permeability transition studies which often rely on 
the light scatter assay as a gauge of inner membrane permeability. These 
findings clearly demonstrate that the absence of mitochondrial large 
amplitude swelling does not indicate an absence of an inner membrane 
permeability. Concluded from this study is that CsA-sensitive 
permeability transition can occur without obvious ultrastructural 
changes and, therefore, monitoring the CsA-sensitive release of 
endogenous matrix solutes, such as glutathione, may be a sensitive 
indicator of permeability transition. 
In Chapters V and VI, the status of NAD(P)H and ATP were 
examined during Ca Pi-induced permeability transition.  Several 
significant observations are reported. The first is that NAD(P)H is 150 
extensively oxidized within a few minutes Ca Pi treatment. This is 
particularly important because it has been assumed heretofore that Ca Pi-
induced permeability transition did not alter the pyridine nucleotide 
redox ratios. The oxidation of pyridine nucleotides occurred 
intramitochondrially followed by the subsequent release of oxidized 
pyridine nucleotides. Release of reduced pyridine nucleotides was not 
observed. The significance of these findings is that extensive oxidation of 
pyridine nucleotides, followed by their release, occurs during Ca Pi 
induced permeability transition. The redox changes in pyridine 
nucleotides may reflect an oxidative stress associated with this 
mitochondrial injury or a mechanism which depletes mitochondria of 
energy. 
Ca Pi-induced permeability transition was also accompanied by the 
rapid depletion of ATP with the concomitant formation of AMP. The 
mechanism of ATP depletion is not currently understood, but is likely an 
important component of this mitochondrial injury. The ability of CsA to 
maintain NAD(P)H and ATP status during Ca Pi-induced permeability 
transition may be important in understanding the mechanism(s) by 
which CsA prevents permeability transition. 
Treatment with metabolic inhibitors in the presence of Ca Pi 
prevented large amplitude swelling but did not prevent inner membrane 
permeability, although solute release was diminished. Under these 
conditions, ADP levels were preserved. Since ADP is an inhibitor of 
permeability transition, the mechanism by which metabolic inhibitors 
prevented large amplitude swelling may be reflected in the maintenance 
of ADP. Concluded from this study is that permeability transition could 1 5 1 
occur to varying degrees, both with and without swelling and varied rates 
of solute release. Maintenance of mitochondrial energy status in the form 
of NAD(P)H, ATP, and ADP may play an important regulatory role in 
permeability transition. 
Directions of future studies include the need to address the 
mechanism by which Ca Pi induced permeability transition oxidizes 
pyridine nucleotides as well as the mechanism of ATP depletion.  Future 
studies might examine superoxide dismutase activity, the effect of 
antioxidants such as vitamin E and BHT, and the measurement of 
reactive oxygen species such as hydrogen peroxide. 
In addition, it would be interesting to investigate whether reduced 
pyridine nucleotides can be loaded into mitochondria. This could be 
accomplished with the use of radiolabelled reduced pyridine nucleotides 
incubated with Ca Pi treated mitochondria followed by the addition of 
CsA. The effect would be to open and close the pore following a short 
incubation with radiolabelled reduced pyridine nucleotides.  This 
experiment would address whether the permeability transition pore is 
selective for oxidized pyridine nucleotides. 
In the experiments described, succinate was the substrate for 
mitochondria. Another set of experiments could involve the use of 
NAD+-linked substrates. This may be revealing of the mechanism by 
which pyridine nucleotide redox status is controlled. 152 
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